Page last updated: 2024-11-04

flucytosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Flucytosine, an antifungal medication, is a synthetic pyrimidine analog that inhibits the synthesis of DNA and RNA in fungal cells. It is primarily used to treat severe fungal infections, particularly cryptococcal meningitis and candidiasis. Flucytosine is absorbed orally and is metabolized in the liver. Its mechanism of action involves its uptake by fungal cells via cytosine permeases. Once inside the cell, flucytosine is converted to 5-fluorouracil by the enzyme cytosine deaminase, which is present in fungi but not in humans. 5-Fluorouracil is a potent inhibitor of thymidylate synthase, an enzyme essential for DNA synthesis. The inhibition of DNA synthesis leads to the death of fungal cells. Flucytosine is often used in combination with other antifungals, such as amphotericin B, to enhance its effectiveness and reduce the risk of resistance. Research continues to explore the use of flucytosine in various fungal infections and investigate its potential in combination therapies. Due to its unique mechanism of action and efficacy against certain fungal infections, flucytosine remains an important therapeutic agent in clinical practice.'

Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3366
CHEMBL ID1463
CHEBI ID5100
SCHEMBL ID24063
SCHEMBL ID14696800
MeSH IDM0008576

Synonyms (199)

Synonym
MLS001076503
HMS3393M04
AB00513969-02
MLS000069463 ,
smr000059047
flucytosinum
CHEBI:5100 ,
flucytosina
4-amino-5-fluoropyrimidin-2(1h)-one
flucytosinum [inn-latin]
2(1h)-pyrimidinone, 4-amino-5-fluoro-)
hsdb 3082
flucitosina [dcit]
nsc 103805
einecs 217-968-7
cas-2022-85-7
NCGC00016599-01
BSPBIO_000868
4-amino-5-fluoro-1h-pyrimidin-2-one
BPBIO1_000956
PRESTWICK3_000934
PRESTWICK2_000934
4-amino-5-fluoro-2(1h)-pyrimidinone
ancotil
nsc103805
fluorcytosine
5-fluorocystosine
5-fc
flucytosine
5-fluorocytosine
5-fluorocytosin
ancobon
ro 2-9915
ro 29915 e/265601
flucytosin
2022-85-7
nsc-103805
2-hydroxy-4-amino-5-fluoropyrimidine
cytosine, 5-fluoro-
wln: t6mvnj dz ef
2(1h)-pyrimidinone, 4-amino-5-fluoro-
fluocytosine
alcobon
cytosine, 5-fluoro- (6ci,7ci,8ci)
6-amino-2-oxo-5-fluoropyrimidine
flucytosone
fluorocytosine
ancotyl
4-amino-5-fluoro-2-hyroxypyrimidine
AB00513969
MLS000759519
cpd000059047 ,
DB01099
STK292386
ancobon (tn)
flucytosine (jp17/usp/inn)
D00323
NCI60_000093
PRESTWICK1_000934
PRESTWICK0_000934
SPBIO_003037
AC-11748
HMS2051M04
HMS2093J05
CHEMBL1463
ro-2-9915
ro-29915
4-amino-5-fluoro-2-hydroxypyrimidine
AKOS005063821
FT-0695664
F0321 ,
HMS1570L10
6-amino-5-fluoro-1h-pyrimidin-2-one
AKOS004912683
HMS2097L10
5-fluoro cytosine
unii-d83282dt06
ec 217-968-7
d83282dt06 ,
flucytosine [usan:usp:inn:ban:jan]
4-amino-5-fluoro-2(1h)-pyrimidine
5-flucytosine
6-amino-5-fluoro-2(1h)-pyrimidinone;5-fluorocytosine
A814346
pharmakon1600-01505429
nsc759130
MLS001424013
nsc-759130
flucytosine [usan)
dtxcid403059
dtxsid3023059 ,
tox21_110515
flucitosina
HMS2233I14
CCG-100837
NCGC00016599-02
ST028644
6-amino-5-fluoro-3-hydropyrimidin-2-one
BCP9000692
5-flurocytosine
BCP0726000281
flucytosine (ancobon)
FT-0601273
NCGC00016599-05
AM20090149
flucytosine [inn]
flucytosine [mart.]
emtricitabine impurity e [who-ip]
flucytosinum [who-ip latin]
5-fluorocytosine [who-ip]
flucytosine [usp-rs]
4-amino-5-fluoropyrimidin-2(1h)-one [who-ip]
flucytosine [usp monograph]
flucytosine [usan]
flucytosine [usp impurity]
flucytosine [orange book]
flucytosine [ep monograph]
flucytosine [who-dd]
flucytosine [hsdb]
flucytosine [who-ip]
flucytosine [mi]
flucytosine [jan]
1ld ,
S1666
AKOS015896898
4-amino-2-hydroxy-5-fluoropyrimidine
4-amino-5-fluoropyrimidin-2-ol
HMS3373L05
5-fluoro-4-imino-1,2,3,4-tetrahydropyrimidin-2-one
CCG-213434
CS-1935
HY-B0139
AB00444223-16
NC00087
SCHEMBL24063
NCGC00016599-04
tox21_110515_1
KS-1060
flucytosine, 5-fluorocytosine
5-fluorocytosine, antibiotic for culture media use only
F-3010
5-fluorocytocine
4-amino-5-fluoro-pyrimidin-2-ol
5-fluoro-cytosine
SCHEMBL14696800
ala-ala-phep-nitroanilide
4-amino-5-fluoro-1,2-dihydropyrimidin-2-one
6-amino-5-fluoropyrimidin-2(1h)-one
OPERA_ID_178
AB00513969_04
AB00513969_03
mfcd00006035
6-amino-5-fluoro-1,2-dihydropyrimidin-2-one
sr-01000721885
SR-01000721885-5
GS-5578
117969-88-7
2-pyrimidinol, 4-amino-5-fluoro- (9ci)
flucytosine, united states pharmacopeia (usp) reference standard
flucytosine, european pharmacopoeia (ep) reference standard
AKOS030241326
HMS3655G17
5-fluorocytosine, vetec(tm) reagent grade, 99%
flucytosine, pharmaceutical secondary standard; certified reference material
flucytosine for system suitability, european pharmacopoeia (ep) reference standard
flucytosine 2.0 mg/ml in methanol
HMS3714L10
SY004438
SW197278-3
bdbm50248003
flourocytosine
ancoban
130256-61-0
5-fluorocytosine form i
5-fluorocytosine form ii
BP-30254
flucytosine,(s)
2-pyrimidinol,4-amino-5-fluoro-
BCP02877
Q238490
BRD-K82143716-001-15-7
EN300-117264
H10295
SB57097
flucytosine 100 microg/ml in acetonitrile:water
flucytosine for system suitability
flucytosinum (latin)
flucytosine (usan:usp:inn:ban:jan)
emtricitabine impurity e
d01ae21
flucytosinum (inn-latin)
flucytosine (mart.)
flucytosine (usp monograph)
flucytosine (ep monograph)
j02ax01
flucytosine (usp-rs)
flucytosine (usp impurity)
2-pyrimidinol, 4-amino-5-fluoro-
Z1201621875

Research Excerpts

Overview

Flucytosine (5-FC) is an antifungal drug used for the treatment of serious infections caused by Candida or Cryptococcus spp. It is a water-soluble, fluorinated pyrimidine that possesses excellent bioavailability.

ExcerptReferenceRelevance
"Flucytosine (5-FC) is an antifungal agent commonly used for treatment of cryptococcosis and several other systemic mycoses. "( Factors Influencing the Nitrogen-Source Dependent Flucytosine Resistance in Cryptococcus Species.
Chang, YC; Khanal Lamichhane, A; Kwon-Chung, KJ; Yang, DH, 2023
)
2.61
"5-flucytosine (5-FC) is an antifungal drug used for the treatment of serious infections caused by Candida or Cryptococcus spp. "( Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory.
Bowker, KE; Lovering, AM; MacGowan, AP; Soltani, M; Sunderland, J; Tobin, CM, 2006
)
1.32
"Flucytosine (5-FC) is a synthetic antimycotic compound, first synthesized in 1957. "( Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions.
Dankert, J; Guchelaar, HJ; Vermes, A, 2000
)
3.19
"Flucytosine is an antifungal drug which can also be given by mouth and carries relatively low toxicity."( Candida osteomyelitis as a complication of parenteral nutrition in an infant. Successful treatment with flucytosine.
Berant, M; Kristal, C; Wagner, Y, 1979
)
1.2
"Flucytosine is a systemic antifungal drug that is readily absorbed from the gastrointestinal tract. "( Flucytosine.
Bennet, JE, 1977
)
3.14
"Flucytosine is a water-soluble, fluorinated pyrimidine that possesses excellent bioavailability."( Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.
Lyman, CA; Walsh, TJ, 1992
)
1
"Flucytosine is an antifungal agent useful in combination with amphotericin B in the treatment of several deeply invasive mycoses. "( Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy.
Francis, P; Walsh, TJ, 1992
)
2.07

Effects

Flucytosine (5FC) has shown synergistic effect with AmB for treatment of some fungal infections, such as cryptococcosis. Its price is a limitation for its use in many regions.

ExcerptReferenceRelevance
"Flucytosine has a narrower spectrum of activity (cryptococcosis, candidosis, cladosporiosis, and chromomycosis) but a preferable route of administration (oral)."( Chemotherapy for the systemic mycoses: the prelude to ketoconazole.
Utz, JP,
)
0.85
"Flucytosine (5FC) has shown synergistic effect with AmB for treatment of some fungal infections, such as cryptococcosis, but again, its price is a limitation for its use in many regions."( Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and
Agreda-Mellon, D; de Oliveira, HC; García-Cambero, JP; Lucio, J; Mendes-Giannini, MJS; Rossi, SA; Zaragoza, O, 2020
)
1.28
"Flucytosine has a narrower spectrum of activity (cryptococcosis, candidosis, cladosporiosis, and chromomycosis) but a preferable route of administration (oral)."( Chemotherapy for the systemic mycoses: the prelude to ketoconazole.
Utz, JP,
)
0.85
"Flucytosine has been reported to interfere with serum creatinine determinations when measured by the Kodak Ektachem-700 analyzer but not when the Jaffe reaction is employed."( Flucytosine interference with serum creatinine determinations.
Sagraves, R; Santeiro, ML; Thompson, DF, 1988
)
2.44

Actions

ExcerptReferenceRelevance
"Flucytosine can cause clinically significant false elevations in serum creatinine when measured by the Kodak Ektachem-700 analyzer."( Flucytosine interference with serum creatinine determinations.
Sagraves, R; Santeiro, ML; Thompson, DF, 1988
)
2.44

Treatment

Treatment with flucytosine with or without fluconazole dissolved in the sole source of drinking water was started on day 2. Animals were sacrificed at 16 days, and the numbers of fungal colonies in the brain were quantified.

ExcerptReferenceRelevance
"Flucytosine-based treatment can be delivered in routine care in a middle-income country with a substantial survival benefit."( Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study.
Black, J; Boretti, L; Garcia, A; Govender, NP; Greene, GS; Harrison, TS; Madua, M; Mashau, RC; Meintjes, G; Meiring, ST; Menezes, C; Nel, J; Quan, VC; Reddy, DL; Shroufi, A; Stacey, S; Trivino-Duran, L; Venter, M, 2022
)
1.82
"Treatment with flucytosine with or without fluconazole dissolved in the sole source of drinking water was started on day 2; animals were sacrificed at 16 days, and the numbers of fungal colonies in the brain were quantified."( Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis.
Bauer, M; Daniel, BE; Diamond, DM; Ding, JC; Graybill, JR; Johnson, D; Larsen, RA; Leal, MA; Najvar, L; Thomas, AM; Williams, BK, 1998
)
0.89
"Treatment with flucytosine led to full recovery."( Candida osteomyelitis as a complication of parenteral nutrition in an infant. Successful treatment with flucytosine.
Berant, M; Kristal, C; Wagner, Y, 1979
)
0.81
"Treatment with flucytosine of 20 patients with fungal infections gave favorable results in four patients with crytococcal infections, two of four patients with disseminated candidiasis, eight of ten patients with urinary tract infections due to Candida albicans and Torulopsis glabrata, and tow of three patients with miscellaneous infections due to Calbicans. "( Treatment of fungal infections with flucytosine.
Harder, EJ; Hermans, PE, 1975
)
0.88

Toxicity

Adverse effects of flucytosine therapy included one case each of reversible nausea, diarrhea, elevated transaminase levels, and thrombocytopenia. Following treatment, she developed a reversible acute cerebellar syndrome.

ExcerptReferenceRelevance
" In three patients, accumulation of toxic levels of 5-FC was related to diminished renal function."( Bone marrow toxicity associated with 5-fluorocytosine therapy.
Frame, PT; Kauffman, CA, 1977
)
0.26
" Adverse effects of flucytosine therapy included one case each of reversible nausea, diarrhea, elevated transaminase levels, and thrombocytopenia."( Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy.
Francis, P; Walsh, TJ, 1992
)
0.95
" One or more toxic drug reactions developed in 103 patients: azotemia (51), renal tubular acidosis (two), leukopenia (30), thrombocytopenia (22), diarrhea (26), nausea/vomiting (10), and hepatitis (13)."( Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis.
Bowles, CA; Cloud, GA; Diasio, RB; Dismukes, WE; Espinel-Ingroff, A; Karam, GH; Shadomy, S; Stamm, AM, 1987
)
0.56
" Following treatment, she developed a reversible acute cerebellar syndrome that was probably secondary to the administration of flucytosine, an adverse effect that has not previously been described [3, 4]."( Acute cerebellopathy as a probable toxic effect of flucytosine.
Barquero Jimenez, S; Cubo Delgado, E; Garcia Urra, D; Sanz Boza, R; Vargas Castrillon, E, 1997
)
0.75
" These results indicate that effective and safe in vivo gene therapy for advanced CRC may be feasible by transferring the CD gene controlled by the CEA promoter followed by 5-FC treatment."( Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter.
Cao, G; Cui, L; Fukui, H; Gao, J; Kikukawa, M; Kuriyama, S; Nakatani, T; Pan, X; Qi, Z; Tsujinoue, H; Zhang, X, 1999
)
0.3
" In order to assess the value of suicidal gene therapy on human prostate carcinoma, the authors studied the toxic effects of HSV-TK gene and CD-TK fusion gene systems on prostate carcinoma cell line PC-3m."( [Toxic effects of HSV-TK and CD-TK suicidal gene systems on prostate carcinoma cells].
Liu, CS; Ma, DX; Xu, CX; Xu, ZS; Zhang, DQ; Zhang, HQ, 2003
)
0.32
" The toxic effects of GCV, 5-FC, and both of them on transfected PC-3m cells were explored by MTT assay; non-transfected PC-3m cells were used as control."( [Toxic effects of HSV-TK and CD-TK suicidal gene systems on prostate carcinoma cells].
Liu, CS; Ma, DX; Xu, CX; Xu, ZS; Zhang, DQ; Zhang, HQ, 2003
)
0.32
"CD-TK fusion suicidal gene system has significant toxic effect on PC-3m cells in vitro, which was superior to HSV-TK alone gene system."( [Toxic effects of HSV-TK and CD-TK suicidal gene systems on prostate carcinoma cells].
Liu, CS; Ma, DX; Xu, CX; Xu, ZS; Zhang, DQ; Zhang, HQ, 2003
)
0.32
"Clinical studies with oncolytic adenoviruses have shown that existing viruses are safe but lack efficacy."( 5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene.
Fuerer, C; Iggo, R, 2004
)
0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Disruptions in all three permease genes consequently conferred the highest degree of resistance, not only towards 5-FC but also to the toxic adenine analogon 8-azaadenine."( Various cytosine/adenine permease homologues are involved in the toxicity of 5-fluorocytosine in Saccharomyces cerevisiae.
Klassen, R; Meinhardt, F; Paluszynski, JP; Rohe, M, 2006
)
0.33
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Anemia remained a concerning adverse effect."( Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis.
Bicanic, T; Bottomley, C; Brouwer, AE; Harrison, TS; Hosseinipour, MC; Jackson, A; Jarvis, JN; Limmathurotsakul, D; Loyse, A; Meintjes, G; Muzoora, C; Phulusa, J; Taseera, K; van der Horst, C; White, NJ; Wilson, D; Wood, R, 2015
)
0.42
" With the exception of a higher incidence of gastrointestinal side effects in the 2000mg cohort, both induction doses of FCZ were safe and well tolerated."( Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS
Aberg, JA; Badal-Faesen, S; Bukuru, A; Clifford, DB; Hogg, E; Komarow, L; Lagat, D; Lalloo, UG; Langat, D; Larsen, RA; Mave, V; McKhann, A; Pillay, S; Samaneka, W; Supparatpinyo, K; Ticona, E, 2023
)
0.91
"Induction phase weight and renal-adjusted doses of 1600mg and 2000mg/day FCZ for CM were safe and well tolerated except for increased GI side effects in the 2000mg/day dose, and had similar times to achieve CSF sterilization, but took significantly longer than AMB."( Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS
Aberg, JA; Badal-Faesen, S; Bukuru, A; Clifford, DB; Hogg, E; Komarow, L; Lagat, D; Lalloo, UG; Langat, D; Larsen, RA; Mave, V; McKhann, A; Pillay, S; Samaneka, W; Supparatpinyo, K; Ticona, E, 2023
)
0.91

Pharmacokinetics

The therapeutic efficacy of flucytosine (5FC) monotherapy and the pharmacodynamic index predictive of efficacy were evaluated in a nonneutropenic mouse model of acute invasive aspergillosis. This pharmacodynamic characteristic coupled with the persistent PAE suggests lower daily dosing may possible without loss of antifungal efficacy.

ExcerptReferenceRelevance
" Pharmacokinetic dose prediction methods have been developed allowing individual dosage adaptation."( Therapeutic drug monitoring and pharmacokinetic dose prediction methods.
Oellerich, M, 1992
)
0.28
" In conclusion, from a pharmacokinetic point of view, all the antifungal agents examined, perhaps with the exception of F, do not offer, when used alone, sufficient guarantees in curing peritonitis."( Pharmacokinetics of antifungal agents.
Bolzonella, R; Contestabile, A; Fabris, A; Gardin, C; Pellanda, MV, 1993
)
0.29
" This pharmacodynamic characteristic coupled with the persistent PAE and the relatively long half-life of flucytosine in humans (> 5 h), suggests lower daily dosing may possible without loss of antifungal efficacy."( In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods.
Klepser, ME; Lewis, RE; Pfaller, MA, 2000
)
0.78
"In vivo pharmacodynamic parameters have been characterized for a variety of antibacterial agents."( In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.
Andes, D; van Ogtrop, M, 2000
)
0.56
", developing thrombocytopenia during 5-FC treatment or remaining within the normal thrombocyte range; individual pharmacokinetic parameters within certain limits; a minimum of three measured 5-FC serum levels)."( Prediction of flucytosine-induced thrombocytopenia using creatinine clearance.
Dankert, J; Guchelaar, HJ; Vermes, A,
)
0.49
" Three pharmacokinetic models were analyzed: a one-compartment with renal elimination (renal model), a one-compartment with renal and metabolic elimination (mixed model), and a two-compartment with renal elimination (two-compartment model)."( Population pharmacokinetics of flucytosine: comparison and validation of three models using STS, NPEM, and NONMEM.
Dankert, J; Guchelaar, HJ; Math t, RA; van der Sijs, IH; Vermes, A, 2000
)
0.59
"The purpose of this study was to define model appropriateness, identifying the individual elements thereof, and to set out a framework within which model appropriateness could be determined for population pharmacokinetic (PPK) models."( Model appropriateness and population pharmacokinetic modeling.
Capparelli, EV; Ette, EI; Kim, YH; Lane, JR; Liu, MJ; Williams, PJ, 2003
)
0.32
"The therapeutic efficacy of flucytosine (5FC) monotherapy and the pharmacodynamic index predictive of efficacy were evaluated in a nonneutropenic mouse model of acute invasive aspergillosis."( Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis.
Meis, JF; Mouton, JW; te Dorsthorst, DT; Verweij, PE, 2005
)
0.9
"In the last decade, the relationship between drug dosing and treatment efficacy for life-threatening fungal infections has been clarified by application of pharmacodynamic principles to the study of antifungal agents."( Pharmacodynamic implications for use of antifungal agents.
Lewis, RE, 2007
)
0.34
" Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect."( Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing.
Denning, DW; Drusano, GL; Hope, WW; Keevil, B; Louie, A; Reed, P; Sharp, A; Walsh, TJ; Warn, PA, 2007
)
0.63
"Therapeutic drug monitoring of any pharmacologic agent should be considered when there is both significant pharmacokinetic variability and strong, clinically relevant, exposure-effect relationships."( Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations.
Andes, D; Smith, J, 2008
)
0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The objective of the current study was to develop two prototype 5FC-CR formulations and evaluate the single-dose (1,500-mg) serum pharmacokinetic profiles of those formulations relative to the profile of the commercially available, immediate-release 5FC product (Ancobon) by the use of a phase 1, open-label, randomized, three-phase, crossover pharmacokinetic study design."( Clinical pharmacokinetics of oral controlled-release 5-fluorocytosine.
Bruce, H; Felton, LA; Pai, MP, 2010
)
0.36
" This article reviews the pharmacokinetic profiles of these drugs in children, with a focus on the age-related changes."( [Pharmacokinetics and pharmacodynamics of antifungal drugs in children].
Jullien, V, 2011
)
0.37
" Finally, the review discusses novel areas of pharmacodynamic investigation in the study and application of combination therapy."( Antifungal pharmacokinetics and pharmacodynamics.
Andes, DR; Lepak, AJ, 2014
)
0.4
" Because of its narrow therapeutic index and risk of toxicity, additional pharmacokinetic studies are needed to determine optimal drug dosing of this medication in patients requiring renal replacement therapy."( Pharmacokinetics of flucytosine in a critically ill patient on continuous venovenous hemodiafiltration.
Adams, KK; Berard-Collins, C; Greene, RA; Lorenzo, MP; Rogers, RD, 2020
)
0.88
" Fluconazole is the only antifungal agent having the pharmacodynamic threshold of efficacy identified in experimental animal models convincingly validated in the clinical setting of invasive candidiasis as well."( From bench to bedside: Perspectives on the utility of pharmacokinetics/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis.
Pea, F, 2020
)
0.56
"In three healthy Beagle dogs receiving 100 mg/kg of 5-fluorocytosine twice daily for 14 days by oral route, non-compartmental pharmacokinetics revealed a terminal elimination half-life of 164."( Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs.
Béguin, J; Degorce, F; Erbs, P; Klonjkowski, B; Kohlhauer, M; Laloy, E; Maurey, C; Moreau, B; Quéméneur, É, 2021
)
0.62

Compound-Compound Interactions

Flucytosine (5FC) in combination with amphotericin B (AB) and fluconazole (FCZ) was studied against 35 yeast isolates in triplicate. Cilofungin, a lipopeptide antifungal agent, was tested for in vitro activity alone and in combination.

ExcerptReferenceRelevance
"Suboptimal doses of amphotericin B in combination with either rifampin or 5-fluorocytosine were better than single-drug therapy in the treatment of disseminated Aspergillus fumigatus infection in mice."( Therapy of murine aspergillosis with amphotericin B in combination with rifampin of 5-fluorocytosine.
Arroyo, J; Kobayashi, GS; Medoff, G, 1977
)
0.26
" Weak inhibitory concentrations of CTM were tested in combination with levels of 5-FC or AMB that alone produced transient antifungal effects followed by rapid recovery of proliferative capacity."( Inhibition of potentially pathogenic yeastlike fungi by clotrimazole in combination with 5-fluorocytosine or amphotericin B.
Beggs, WH; Sarosi, GA; Steele, NM, 1976
)
0.26
"Cilofungin, a lipopeptide antifungal agent, was tested for in vitro activity alone and in combination with ketoconazole, itraconazole, flucytosine and amphotericin B against 102 clinical isolates of Candida species."( In vitro comparison of cilofungin alone and in combination with other antifungal agents against clinical isolates of Candida species.
Cobbs, CG; Dismukes, WE; Lank, KM; Smith, KR, 1991
)
0.48
"Cilofungin was combined with amphotericin B or flucytosine to determine if synergistic inhibition or killing occurred against 50 strains of various Candida species."( The effect of cilofungin (LY 121019) in combination with amphotericin B or flucytosine against Candida species.
Bradley, SF; Bulo, AN; Kauffman, CA, 1989
)
0.76
"Cilofungin was combined with amphotericin B or flucytosine to determine if synergistic inhibition or killing occurred against 50 strains of various Candida species."( The effect of cilofungin (LY 121019) in combination with amphotericin B or flucytosine against Candida species.
Bradley, SF; Bulo, AN; Kauffman, CA, 1989
)
0.76
"The antifungal activity of amphotericin B (AMB), mepartricin (MEPA), 5-fluorocytosine (5FC) and three imidazoles was tested in combination with each of four quinolones against 60 clinical yeast isolates."( In-vitro activity of antifungal agents in combination with four quinolones.
Petrou, MA; Rogers, TR, 1988
)
0.27
" In vitro studies showed that 5-FC combined with CDase induced significant growth-inhibitory effects on the cultured glioma cells."( Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules.
Ito, T; Katsuragi, T; Kawamoto, K; Kawamura, Y; Matsumura, H; Nishiyama, T; Ohyama, A; Sakai, T; Yamamoto, N, 1985
)
0.27
" Flucytosine combined with amphotericin B produced little or no reduction of the MICs at which 90% of the strains were inhibited compared with amphotericin B alone."( In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp.
Gerding, DN; Harris, C; Hughes, CE; Moody, JA; Peterson, LR, 1984
)
1.18
" We conducted a prospective, open-label clinical trial involving persons with AIDS to determine whether the rate of clinical success would improve when fluconazole (400 mg daily) was combined with flucytosine (150 mg/kg daily)."( Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.
Bauer, M; Bozzette, SA; Forthal, D; Haghighat, D; Jones, BE; Larsen, RA; Leal, MA; Leedom, JM; McCutchan, JA; Tilles, JG, 1994
)
0.78
"Two different flucytosine (5-FC) treatment regimens, one by itself and the other in combination with fluconazole (FLCZ) were compared in chemotherapy against mycotic infections in 60 patients with hematological diseases."( [A comparative clinical study on flucytosine alone and in combination with fluconazole in hematological malignancies: a multicenter study using the envelope method].
Ariyoshi, H; Hamajima, N; Hotta, T; Kodera, Y; Murate, T; Naito, K; Naoe, T; Ogura, M; Saito, H; Tanaka, M, 1994
)
0.93
" This demonstrates that a major increase in intratumoral drug concentrations can be attained with an monoclonal antibody-enzyme conjugate in combination with an anticancer prodrug compared to systemic drug therapy."( Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine.
Cosand, WL; Kerr, DE; MacMaster, JF; Senter, PD; Smith, VF; Wallace, PM, 1994
)
0.29
" This study evaluated the antifungal efficacy of amphotericin B colloidal dispersion (ABCD) combined with flucytosine with and without fluconazole in a murine model of cryptococcal meningitis."( Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis.
Bauer, M; Daniel, BE; Diamond, DM; Ding, JC; Graybill, JR; Johnson, D; Larsen, RA; Leal, MA; Najvar, L; Thomas, AM; Williams, BK, 1998
)
0.77
"The effect of drugs in combination on the growth of Candida glabrata was studied in solid medium by demonstration of reduced or enhanced growth, and in liquid medium by determination of interaction indices."( The effect of antifungal drugs in combination on the growth of Candida glabrata in solid and liquid media.
Kerridge, D; Siau, H, 1998
)
0.3
" Since lactoferrin is one of the nonspecific host defense factors present in saliva that exhibit antifungal activity, we studied the antifungal effects of human, bovine, and iron-depleted lactoferrin in combination with fluconazole, amphotericin B, and 5-fluorocytosine in vitro against clinical isolates of Candida species."( Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates.
de Vries, HG; Eikelboom, MC; Kuipers, ME; Meijer, DK; Swart, PJ, 1999
)
0.3
" Flucytosine combined with amphotericin B produced little or no reduction of the MIC compared with amphotericin B alone."( Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp.
Chaiprasert, A; Prariyachatigul, C; Rungsipanuratn, W; Srimuang, S; Tanphaichitra, D, 2000
)
1.22
" We previously used an adenoviral vector under control of the cytomegalovirus promoter (AdCMVCD) encoding the CD gene in combination with 5-FC and a single fraction of radiation exposure to enhance cytotoxicity to human cholangiocarcinoma cells in vitro and in vivo."( Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models.
Buchsbaum, DJ; Curiel, DT; Gebert, J; Grizzle, WE; Haack, K; Mayo, MS; Pederson, LC; Stackhouse, MA; Vickers, SM, 2000
)
0.31
" In combination with amphotericin B, 5-FC can be used to treat severe systemic mycoses, such as cryptococcosis, candidosis, chromoblastomycosis and aspergillosis."( Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions.
Dankert, J; Guchelaar, HJ; Vermes, A, 2000
)
1.75
"To study the effect of X-ray on gene transfer and the antitumoral effect of X-ray combined with suicide gene therapy on colorectal carcinoma cells."( [X-ray combined with cytosine deaminase suicide gene therapy enhances killing of colorectal carcinoma cells in vitro].
An, P; Cai, H; Chen, G; Guo, W; Li, S; Yu, B, 2002
)
0.31
" Antitumoral effect of X-ray combined with CD and 5-FC on colorectal carcinoma cells was tested by MTT."( [X-ray combined with cytosine deaminase suicide gene therapy enhances killing of colorectal carcinoma cells in vitro].
An, P; Cai, H; Chen, G; Guo, W; Li, S; Yu, B, 2002
)
0.31
" Middle-dose radiation combined with CD and 5-FC could kill 99 percent of colorectal carcinoma cells, while in the control group, 5-FC only killed 15 percent of colorectal carcinoma cells which were transduced with CD gene."( [X-ray combined with cytosine deaminase suicide gene therapy enhances killing of colorectal carcinoma cells in vitro].
An, P; Cai, H; Chen, G; Guo, W; Li, S; Yu, B, 2002
)
0.31
"X-Ray combined with suicide gene therapy may be used as a promising method for treating colorectal neoplasm."( [X-ray combined with cytosine deaminase suicide gene therapy enhances killing of colorectal carcinoma cells in vitro].
An, P; Cai, H; Chen, G; Guo, W; Li, S; Yu, B, 2002
)
0.31
" The efficacy of flucytosine (5FC) in combination with amphotericin B (AB) and fluconazole (FCZ) was studied against 35 yeast isolates in triplicate (Candida albicans [n = 9], Candida glabrata [n = 9], Candida krusei [n = 9], and Cryptococcus neoformans [n = 8]) using a broth microdilution checkerboard method and measuring growth after 48 h by a spectrophotometer."( In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach.
Bergervoet, M; Meis, JF; Meletiadis, J; Mouton, JW; Punt, NC; Te Dorsthorst, DT; Verweij, PE, 2002
)
0.96
"75 mg/kg), administered singly or in combination with flucytosine (100 mg/kg)."( Effects of fluconazole singly and in combination with 5-fluorocytosine or amphotericin B in the treatment of cryptococcal meningoencephalitis in an intracranial murine model.
Ghannoum, MA; Hossain, MA; Long, L; Mukherjee, PK; Reyes, G, 2002
)
0.56
" Amphotericin B was combined with flucytosine and ciprofloxacin, whereas itraconazole was combined with ciprofloxacin, levofloxacin, lomefloxacin and sulfadiazine."( In vitro activity of amphotericin B and itraconazole in combination with flucytosine, sulfadiazine and quinolones against Exophiala spinifera.
Afeltra, J; de Hoog, GS; Rijs, AJ; Verweij, PE; Vitale, RG, 2003
)
0.83
" Gene therapy combined with radiation represents a new approach to cancer treatment."( Combination with CD/5-FC gene therapy enhances killing of human bladder-cancer cells by radiation.
Fujisawa, M; Gotoh, A; Hinata, N; Kamidono, S; Matsumoto, A; Matsuo, M; Okada, H; Shirakawa, T; Zhang, Z, 2003
)
0.32
"In the present study, we demonstrated that CD/5-FC gene therapy combined with radiation therapy enhances cell killing of human bladder-cancer cells in in vitro and in vivo animal models."( Combination with CD/5-FC gene therapy enhances killing of human bladder-cancer cells by radiation.
Fujisawa, M; Gotoh, A; Hinata, N; Kamidono, S; Matsumoto, A; Matsuo, M; Okada, H; Shirakawa, T; Zhang, Z, 2003
)
0.32
" Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect."( Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing.
Denning, DW; Drusano, GL; Hope, WW; Keevil, B; Louie, A; Reed, P; Sharp, A; Walsh, TJ; Warn, PA, 2007
)
0.63
" We conducted a prospective phase II dose escalation study employing doses of fluconazole ranging from 800 to 2000 mg daily for 10 weeks used alone or combined with flucytosine at 100 mg/kg per day for the first 4 weeks."( Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis.
Bozzette, SA; Haubrich, R; Larsen, RA; Leal, MA; Leedom, JM; McCutchan, JA; Milefchik, E; Tilles, JG, 2008
)
0.82
"To study the antitumor and distant bystander effects of cationic liposome-mediated cytosine deaminase (CD)/5-fluorocytosine (5-FC) suicide gene system combined with interferon-gamma (IFN-gamma) in vivo."( [Anti-tumor and bystander effects of cationic liposome-mediated CD/5-FC suicide gene system combined with interferon-gamma in vivo].
Liu, GY; Lu, YZ; Luo, Q; Zhang, SE, 2008
)
0.35
"42%; when combined with IFN-gamma, the inhibition rate increased significantly to 87."( [Anti-tumor and bystander effects of cationic liposome-mediated CD/5-FC suicide gene system combined with interferon-gamma in vivo].
Liu, GY; Lu, YZ; Luo, Q; Zhang, SE, 2008
)
0.35
"When combined with IFN-gamma, CD/5-FC suicide system has stronger anti-tumor and distant bystander effects."( [Anti-tumor and bystander effects of cationic liposome-mediated CD/5-FC suicide gene system combined with interferon-gamma in vivo].
Liu, GY; Lu, YZ; Luo, Q; Zhang, SE, 2008
)
0.35
" The major finding of this study is that the CD-annexin V fusion protein in combination with the prodrug 5-fluorocytosine has significant cytotoxic activity against endothelial cells and two breast cancer cells lines in vitro that expose phosphatidylserine on their surface."( Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine.
Harrison, RG; Van Rite, BD, 2011
)
0.37
" The objective of this study was to compare the survival benefit between 5-FC (flucytosine) and fluconazole as second-line drugs given in combination with AmB."( Comparison of flucytosine and fluconazole combined with amphotericin B for the treatment of HIV-associated cryptococcal meningitis: a systematic review and meta-analysis.
Lin, DF; Lu, X; Shen, C; Yao, ZW, 2014
)
0.99
"Toca 511, a gamma retroviral replicating vector encoding cytosine deaminase, used in combination with 5-fluorocytosine (5-FC) kills tumor by local production of 5-fluorouracil (5-FU), inducing local and systemic immunotherapeutic response resulting in long-term survival after cessation of 5-FC."( Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Gruber, HE; Huang, TT; Ibañez, CE; Jolly, DJ; Lopez Espinoza, F; Mendoza, D; Robbins, JM; Yagiz, K, 2016
)
0.43
"We investigated the effects of lomustine combined with Toca 511 + 5-FC in syngeneic orthotopic glioma models."( Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Gruber, HE; Huang, TT; Ibañez, CE; Jolly, DJ; Lopez Espinoza, F; Mendoza, D; Robbins, JM; Yagiz, K, 2016
)
0.43
" Rejection of tumor rechallenge occurred after treatment with Toca 511 + 5-FC or combined with lomustine, but not with lomustine + 5-FC."( Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Gruber, HE; Huang, TT; Ibañez, CE; Jolly, DJ; Lopez Espinoza, F; Mendoza, D; Robbins, JM; Yagiz, K, 2016
)
0.43
" In the present study, antitumor effects of APS001F plus 5-FC (APS001F/5-FC) in combination with anti-PD-1 monoclonal antibody were investigated using a CT26 syngeneic mouse model."( Potentiated antitumor effects of APS001F/5-FC combined with anti-PD-1 antibody in a CT26 syngeneic mouse model.
Matsumura, T; Nakamura, T; Seki, Y; Shimizu, H; Shioya, K; Taniguchi, S, 2021
)
0.62
"In the present study, we compared the efficacy of liposomal amphotericin B (L-AMB) alone and in combination with flucytosine (5-FC) for the induction treatment of CM in patients without HIV."( Comparison of liposomal amphotericin B alone and in combination with flucytosine in the treatment of non-HIV Cryptococcal meningitis: A nationwide observational study.
Ashizawa, N; Fushimi, K; Hidaka, Y; Hirayama, T; Hosogaya, N; Iwanaga, N; Izumikawa, K; Morimoto, S; Mukae, H; Takazono, T; Takeda, K; Tashiro, M; Yamamoto, K; Yanagihara, K, 2022
)
1.17
"Our previous study explored Amphotericin B (AMB) plus 5-flucytosine (5-FC) combined with fluconazole (FLU) therapy in the induction period, which seemed to be better than the previous AMB + 5-FC antifungal therapy in non-HIV and non-transplant-associated CM."( Amphotericin B plus fluorocytosine combined with voriconazole for the treatment of non-HIV and non-transplant-associated cryptococcal meningitis: a retrospective study.
Jiang, Y; Li, M; Liu, J; Peng, F; Su, X; Wang, A; Wang, Y; Xu, X; Yang, L, 2022
)
0.97
"AMB plus 5-FC combined with VOR may rapidly improve clinical manifestation, decrease CSF OP and clear the cryptococci in CSF during the early phase, substantially shorten the hospitalization time, and reduce the incidences of hypokalemia and gastrointestinal discomfort."( Amphotericin B plus fluorocytosine combined with voriconazole for the treatment of non-HIV and non-transplant-associated cryptococcal meningitis: a retrospective study.
Jiang, Y; Li, M; Liu, J; Peng, F; Su, X; Wang, A; Wang, Y; Xu, X; Yang, L, 2022
)
0.72
" Laboratory adverse events (grade 3 or 4), such as severe anemia, were less frequent with VCZ + 5FC use than with AmB-D combined with 5FC or Flu use."( Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China.
Chen, Y; Harypursat, V; Lan, K; Lu, Y; Wu, Y; Xu, X; Yang, T; Yu, J; Zeng, Q; Zhang, W; Zhao, T; Zhou, G, 2022
)
0.96
"Our results suggest that AmB-D combined with 5FC remains the more efficacious induction regimen compared to AmB-D plus Flu, and that VCZ + 5FC might be a potential alternative when the standard regimen is not readily available, accessible, tolerated, or effective."( Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China.
Chen, Y; Harypursat, V; Lan, K; Lu, Y; Wu, Y; Xu, X; Yang, T; Yu, J; Zeng, Q; Zhang, W; Zhao, T; Zhou, G, 2022
)
0.96

Bioavailability

ExcerptReferenceRelevance
" Because of its metabolism by intestinal and other cells, 5-FU has an inconsistent bioavailability that limits its oral use."( 5-Fluoro-2-pyrimidinone, a liver aldehyde oxidase-activated prodrug of 5-fluorouracil.
Chang, CN; Chang, CP; Chen, HX; Cheng, YC; Guo, X; Lerner-Tung, M; Lin, TS; Pizzorno, G; Zhu, JL, 1995
)
0.29
" The bioavailability of fluconazole is much less varied although validation of compliance is a situation where obtaining serum concentrations may provide additional information."( Therapeutic drug monitoring of systemic antifungal therapy.
Gore, SJ; Graybill, JR; Hardin, TC; Summers, KK, 1997
)
0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" 5-FC is well absorbed after oral administration, penetrates into body tissues well and is excreted mainly by the kidneys."( Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions.
Dankert, J; Guchelaar, HJ; Vermes, A, 2000
)
1.75
" The bioavailability of the oral formulation may be reduced in late-stage HIV-infected patients in Thailand."( Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
Brouwer, AE; Chierakul, W; Day, N; Harrison, TS; Johnson, E; Rajanuwong, A; Teparrukkul, P; van Kan, HJ; Wuthiekanun, V, 2007
)
0.65
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Flucytosine dosed at 25 mg/kg of actual body weight every 12 hours during CVVHDF conferred therapeutic levels with no appreciable toxicities.

ExcerptRelevanceReference
" Data on biotransformation, kinetics and dosage are reported."( [Pulmonary mycoses; laboratory diagnosis, antimycotic therapy].
Bartmann, K, 1977
)
0.26
" High-dose T-cin controls survived despite having received a cumulative dosage of more than twice the reported (LD(50)) mean lethal dose value."( Comparative study of trichothecin, amphotericin B, and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo.
Hariri, A; Larsh, HW; Sneller, MR; Sorenson, WG, 1977
)
0.26
" Therefore, amphotericin B dosage does not have to be adapted to kidney function, which is the case for flucytosine."( Pharmacokinetics of amphotericin B and flucytosine.
Polak, A, 1979
)
0.74
"The use of the antifungal agent flucytosine has been associated with dose-related hepatotoxicity and bone marrow depression, and measurement of plasma concentrations is useful in determining dosage schedules."( Assay of flucytosine (5-fluorocytosine) in human plasma by high-pressure liquid chromatography.
Bury, RW; Mashford, ML; Miles, HM, 1979
)
0.96
" A reduction in the dosage of the 5-fluorocytosine resulted in a marked decrease in the excretion of urinary gravel which was shown to be a coprecipitate of 5-fluorocytosine and uric acid."( Crystalluria during flucytosine therapy.
Chinwah, PM; Cobcroft, R; Williams, KM, 1979
)
0.58
" Three patients experienced leukopenia, which was readily reversed when the dosage of 5-FC was decreased and the serum concentration was lowered."( Bone marrow toxicity associated with 5-fluorocytosine therapy.
Frame, PT; Kauffman, CA, 1977
)
0.26
" Possibly only patients with cellular immunologic defects are susceptible of a favourable response, moreover it is thinkable that the quality of Transfer Factor and the dosage administered must play a role."( Clinical and immunological improvement in a patient with chronic mucocutaneous candidiasis treated with transfer factor.
Aiuti, F; Businco, L; Cavalieri, R; Franchi, F; Frati, C; Rezza, E,
)
0.13
" The proper duration and dosage and the combination of antifungal drugs have not been clearly defined."( [Primary Aspergillus endocarditis. Apropos of a case and review of the international literature].
Cajot, MA; Gosselin, B; Goullard, L; Koussa, A; Marquette, F; Pol, A; Roux, JP; Soots, G; Warembourg, H, 1992
)
0.28
" Liposomal Amphotericin B allowing higher dosage by lower toxicity appears effective as salvage treatment especially in aspergillosis which also responds to Itraconazole available as oral formulation so far."( Antifungal treatment strategy in leukemia patients.
Büchner, T; Roos, N, 1992
)
0.28
" Dosing recommendations are based on the specific infection and the status of the host."( Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.
Lyman, CA; Walsh, TJ, 1992
)
0.28
" Serial serum levels of flucytosine measured by a creatinine iminohydrolase assay permitted reliable dosage adjustment."( Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy.
Francis, P; Walsh, TJ, 1992
)
0.93
" Pharmacokinetic dose prediction methods have been developed allowing individual dosage adaptation."( Therapeutic drug monitoring and pharmacokinetic dose prediction methods.
Oellerich, M, 1992
)
0.28
" Dose-response studies evaluating [3H]thymidine incorporation or cloning efficiency demonstrated profound inhibition at and above 65 micrograms of 5-fluorocytosine per ml."( Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system.
Blaese, RM; Kilstrup, M; Mullen, CA, 1992
)
0.28
" The data from such PAFE assays may be useful for determining in vivo treatment regimens, since longer PAFEs may allow for intermittent dosing instead of continuous drug administration."( Turbidometric characterization of the postantifungal effect: comparative studies with amphotericin B, 5-fluorocytosine and miconazole on Candida albicans.
Ichihara, Y; Kurita, N; Mikami, Y; Miyaji, M; Scalarone, GM; Yazawa, K,
)
0.13
" The spectrophotometric methods were applied successfully to the quality control of commercial dosage forms of flucytosine and the results were compared with those obtained by a HPLC procedure (cyano column) developed as a reference method."( Analysis of flucytosine dosage forms by derivative UV spectroscopy and liquid chromatography.
Bonazzi, D; Cavrini, V; Di Pietra, AM, 1991
)
0.87
" We also recommend an initial 24-hour dosing interval for amphotericin B and 5-fluorocytosine."( Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates.
Baley, JE; Blumer, JL; Jacobs, MR; Kliegman, RM; Meyers, C, 1990
)
0.28
" The pharmacologic profiles, mechanisms of action, pharmacokinetics, clinical indications for use, dosage recommendations, side effects, and drug interactions for these agents are presented."( The pharmacology of agents used in the treatment of pulmonary mycoses.
Borgers, M; Cauwenbergh, G; Vanden Bossche, H, 1986
)
0.27
" The in vitro activity of LY121019 is marked by a paradoxical dose-response with isolates of Candida albicans and Candida tropicalis and is influenced by choice of inoculum size, time and temperature of incubation, medium composition, and pH."( Influence of in vitro susceptibility testing conditions on the anti-candidal activity of LY121019.
Gerarden, T; Pfaller, MA; Wenzel, RP; Yu, M, 1988
)
0.27
" We found a linear relationship between the elimination rate constant and the FR, and based on these data, a dosage schedule is proposed regarding the use of 5-FC in patients treated with CH."( 5-Fluorocytosine kinetics in patients with acute renal failure undergoing continuous hemofiltration.
Glöckner, WM; Ittel, TH; Legler, UF; Polak, A; Sieberth, HG, 1987
)
0.27
" FOA in different dosage forms was applied topically 2 to 3 times daily for 30 days."( Studies on the antimycotic activity of 5-fluoroorotic acid.
Golovinsky, E; Karamanov, G; Maneva, L; Nikolova, K, 1987
)
0.27
" The system was dosed initially and after 2 weeks of chronic exposure to 5-fluorocytosine with radiolabeled 5-fluorocytosine."( Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora.
Diasio, RB; Federle, TW; Harris, BE; Manning, BW, 1986
)
0.27
" Miconazole was found to be an effective agent in some patients when administered in a dosage of 2400 mg/day."( Fungal endophthalmitis in narcotic abusers. Medical and surgical therapy in 10 patients.
Billson, F; Clifton-Bligh, P; Gallo, J; Gregory-Roberts, J; Grunstein, H; Playfair, J, 1985
)
0.27
" On the basis of our findings we have determined the optimal dosage that achieves desired concentrations."( [Monitoring of treatment involving 5-fluorocytosine].
Bernard, E; Chichmanian, RM; Dellamonica, P; Fournier, JP; Garraffo, R; Lapalus, P; Le Fichoux, Y; Marty, P, 1985
)
0.27
" Mild to moderate renal impairment produced marked increases in peak 5-FC concentrations in the serum of a group of eight patients on three different dosage schedules."( Pharmacological studies with 5-fluorocytosine.
Bennett, JE; Block, ER, 1972
)
0.25
" Renal clearance of 5-FC was about 75% of the creatinine clearance and a corresponding modification of drug dosage should be made in patients with renal insufficiency."( Use of 5-fluorocytosine in patients with impaired renal function.
Dawborn, JK; Page, MD; Schiavone, DJ, 1973
)
0.25
" Cryptococcemia was strongly associated with corticosteroid therapy, especially when the dosage had recently been increased."( Cryptococcemia.
Durack, DT; Gallis, HA; Perfect, JR, 1983
)
0.27
" It is clearly seen from the table that the optimal modern therapy of systemic mycoses is a combination of 5-fluorocytosine in a normal dosage and amphotericin B at reduced dosage."( [Antimycotic chemotherapy in weakened resistance].
Wegmann, T, 1984
)
0.27
" Although appropriate therapy of fungal peritonitis in patients undergoing CAPD still remains controversial, both for the drug of choice and for the dosage to be used, our study indicates that a 5-week course of oral 5-fluorocytosine (5-FC) may obviate the need to remove the peritoneal catheter during the management of peritonitis caused by susceptible strains of T glabrata."( Torulopsis glabrata peritonitis complicating continuous ambulatory peritoneal dialysis: successful management with oral 5-fluorocytosine.
Cecchin, E; Chiaradia, V; De Marchi, S; Franceschin, A; Panarello, G; Santini, G; Tesio, F, 1984
)
0.27
"A system is described for measurement of relative inhibition factors (RIFs) for antifungal agents--that is, the area under a fixed portion of the antifungal dose-response curve, expressed as a percentage of the area under the dose-response curve for a theoretical noninhibitory substance."( Relative inhibition factors--a novel approach to the assessment of antifungal antibiotics in vitro.
Abbott, AB; Odds, FC, 1984
)
0.27
" Serum drug concentration determination is necessary to devise an optimal dosage regimen for the patient."( Elimination of flucytosine by continuous hemofiltration.
Kronfol, NO; Lau, AH, 1995
)
0.64
" Various physiologic variables influence flucytosine pharmacokinetics, and there are no guidelines for dosing the agent in obese patients."( Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection.
Gillum, JG; Johnson, M; Lavoie, S; Venitz, J,
)
1.84
"The antifungal substance flucytosine (5-fluorocytosine) was chosen as a model drug for studying the development of a controlled-release capsule dosage form based mainly on in vitro drug release tests."( Use of in vitro release tests for the prediction of the in vivo behavior and the development of flucytosine controlled-release capsules.
Bonny, JD; Kyowa, M, 1995
)
0.81
" The bioavailability of 5-FP given orally was 100% at a dosage of 25 mg/kg and 78% at a dosage of 50 mg/kg."( 5-Fluoro-2-pyrimidinone, a liver aldehyde oxidase-activated prodrug of 5-fluorouracil.
Chang, CN; Chang, CP; Chen, HX; Cheng, YC; Guo, X; Lerner-Tung, M; Lin, TS; Pizzorno, G; Zhu, JL, 1995
)
0.29
" Amphotericin B is often considered as the gold standard treatment despite its high toxicity particularly with high dosage (1-1."( [Curative treatment of invasive aspergillosis].
Dupont, B, 1994
)
0.29
" These findings may have implications for dosing antifungal agents in systemic yeast infections."( The postantibiotic effect of antifungal agents against common pathogenic yeasts.
Craig, WA; Gudmundsson, S; Turnidge, JD; Vogelman, B, 1994
)
0.29
" Tumor xenografts composed of CD-expressing cells can selectively generate tumor levels of > 400 microM 5FUra when the host mouse is dosed with nontoxic levels of 5FCyt."( Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase.
Austin, EA; Davis, ST; Good, SS; Huber, BE; Richards, CA, 1994
)
0.29
" In a prospective study we performed 65 dosage predictions on 30 patients by use of a 3-point method previously developed for aminoglycoside dosage adaptation."( Individualization of 5-fluorocytosine therapy.
Demertzis, S; Freund, M; Oellerich, M; Petersen, D; Schumann, G,
)
0.13
" The optimal dosage of fluconazole and the impact of combination with flucytosine are not known."( Treatment of experimental cryptococcal meningitis with fluconazole: impact of dose and addition of flucytosine on mycologic and pathophysiologic outcome.
Elliott, BR; Kartalija, M; Kaye, K; Liu, Q; Sande, MA; Täuber, MG; Tureen, JH, 1996
)
0.74
" Our results suggest that fresh serum positively influenced PAFE which may be an important factor in determining the dosing regimen for infection by yeasts."( Influence of human serum on the postantifungal effect of four antifungal agents on Candida albicans.
García, MT; Lima, JE; Mínguez, F; Prieto, J,
)
0.13
"The stability of drugs commonly prescribed for use in oral liquid dosage forms but not commercially available as such was studied."( Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids.
Allen, LV; Erickson, MA, 1996
)
0.53
" The need to modify fluconazole dosage in patients receiving continuous venovenous haemofiltration is discussed."( Hazards of inadequate fluconazole dosage to treat deep-seated or systemic Candida albicans infection.
Barnes, RA; Flanagan, PG, 1997
)
0.3
" Lipid preparations of amphotericin B have reduced the toxicity of this agent, but some issues of dosage and efficacy remain."( Therapy of deep fungal infection in haematological malignancy. Working Party of the British Society for Antimicrobial Chemotherapy.
, 1997
)
0.3
" Fluconazole, at a dosage equivalent to 800 mg/day administered orally, and flucytosine, also given orally, led to a clinical response and a steady decline in serum cryptococcal antigen titer, which became negative at 6 weeks of therapy."( Successful treatment of disseminated cryptococcosis in a liver transplant recipient with fluconazole and flucytosine, an all oral regimen.
Gayowski, T; Marino, IR; Singh, N, 1998
)
0.74
" The dosing schedule required 30 days; neither addition of an enzyme inhibitor that increases the half-life of fluorocytosine nor intralumenal drug delivery is effective in shortening (to 15 days) the protocol."( Toxin gene-mediated growth inhibition of lung adenocarcinoma in an animal model of pleural malignancy.
Batra, RK; Boucher, RC; Hoganson, DK; Matsui, H, 1998
)
0.3
" Further, these results may have an important bearing on dosage regimens currently employed in treating oral candidosis."( Adhesion of oral Candida albicans isolates to denture acrylic following limited exposure to antifungal agents.
Ellepola, AN; Samaranayake, LP, 1998
)
0.3
" The recent move to once-daily dosing means that criteria for therapeutic drug monitoring need to be redefined."( The therapeutic monitoring of antimicrobial agents.
Barclay, ML; Begg, EJ; Kirkpatrick, CJ, 1999
)
0.3
" This pharmacodynamic characteristic coupled with the persistent PAE and the relatively long half-life of flucytosine in humans (> 5 h), suggests lower daily dosing may possible without loss of antifungal efficacy."( In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods.
Klepser, ME; Lewis, RE; Pfaller, MA, 2000
)
0.78
" These parameters have been studied in correlation with in vivo outcomes in order to determine (i) which dosing parameter is predictive of outcome and (ii) the magnitude of that parameter associated with efficacy."( In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.
Andes, D; van Ogtrop, M, 2000
)
0.56
" New interim measures of therapeutic response would be particularly useful in the development of cancer chemosensitization gene therapy by facilitating optimization of gene transfer protocols and prodrug dosing schedules."( Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy.
Chenevert, TL; Hamstra, DA; Jonas, SJ; Rehemtulla, A; Rice, DJ; Ross, BD; Stegman, LD; Stout, KL, 2000
)
0.31
" Additionally, we tested this gene therapy/prodrug treatment strategy employing a fractionated radiation dosing schema in animal models of WiDr colon carcinoma and SK-ChA-1 cholangiocarcinoma."( Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models.
Buchsbaum, DJ; Curiel, DT; Gebert, J; Grizzle, WE; Haack, K; Mayo, MS; Pederson, LC; Stackhouse, MA; Vickers, SM, 2000
)
0.31
" In situ transduction of the CD gene, followed by systemic use of 5-FC at a daily dosage of 300 mg/kg for 14 days, was performed two days later."( In situ transduction of cytosine deaminase gene followed by systemic use of 5-fluorocytosine inhibits tumor growth and metastasis in orthotopic prostate cancer mouse models.
Yin, L; Zhang, Y; Zhang, Z; Zhao, F, 2002
)
0.31
" Ventricular drainage and amphotericin B intraventricularly via an implanted tube into dilated ventricle could improve the clinical condition of serious cryptococcal meningitis and decrease the dosage of systemic use of amphotericin B, therefore, reduce the side-effects of the drugs."( [A clinical study of 26 cases of cryptococcal meningitis].
Li, T; Liu, Z; Qin, S; Sheng, R; Wang, A, 2002
)
0.31
" Clinical improvement was apparent for 13 months during steroid therapy until the slow taper reached a dosage of 20 mg/day."( Cryptococcal infection in sarcoidosis.
Gibson, LE; Kist, JM; Mehrany, K, 2002
)
0.31
" Previous findings induce the necessity to optimize tumor selectivity and bacterial dosing in relation to tumor volume and intratumoral therapeutic gene expression."( Optimization of tumor-targeted gene delivery by engineered attenuated Salmonella typhimurium.
Anne, J; Lambin, P; Landuyt, W; Mei, S; Theys, J,
)
0.13
" This article provides an up-to-date review on the clinical pharmacology, indications, and dosage recommendations of approved and currently investigational therapeutics for treatment of invasive fungal infections in adult and pediatric patients."( Clinical pharmacology of antifungal compounds.
Gea-Banacloche, JC; Glasmacher, A; Groll, AH; Just-Nuebling, G; Maschmeyer, G; Walsh, TJ, 2003
)
0.32
" From the PPK model, the range of expected serum concentrations based on two widely used dosing methods (Sanford and the University of California at San Diego [UCSD]) was simulated (Pharsight Trial Designer software)."( Model appropriateness and population pharmacokinetic modeling.
Capparelli, EV; Ette, EI; Kim, YH; Lane, JR; Liu, MJ; Williams, PJ, 2003
)
0.32
" This article reviews recent pertinent data with regard to dosing guidelines, efficacy, and toxicities of available systemic antifungal agents in the newborn."( Antifungal pharmacotherapy for neonatal candidiasis.
Bliss, JM; Gigliotti, F; Wellington, M, 2003
)
0.32
" These support the use of these drugs in neonates, but because of their largely noncomparative nature they can not define the optimal dosage or duration of therapy."( Antifungals in systemic neonatal candidiasis.
Aranda, JV; Frattarelli, DA; Giacoia, GP; Reed, MD, 2004
)
0.32
"0) 2 h prior to the start of therapy and were treated for 7 days with different 5FC dosing regimens."( Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis.
Meis, JF; Mouton, JW; te Dorsthorst, DT; Verweij, PE, 2005
)
0.61
" An in vivo drug exposure breakpoint for 5FC was apparent when serum levels were above the MIC for 45% of the dosing interval."( Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect.
Denning, DW; Drusano, GL; Hope, WW; Howard, S; Kasai, M; Louie, A; Sharp, A; Walsh, TJ; Warn, PA, 2006
)
0.58
" The consequences of a delay in the administration of amphotericin B, flucytosine, or micafungin were studied by defining dose-response relationships."( Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.
Denning, DW; Drusano, GL; Hope, WW; Louie, A; Moore, CB; Sharp, A; Walsh, TJ; Warn, PA, 2007
)
0.57
" The results suggest that either formulation can be used safely at this dosage in a developing country setting, without drug concentration monitoring."( Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
Brouwer, AE; Chierakul, W; Day, N; Harrison, TS; Johnson, E; Rajanuwong, A; Teparrukkul, P; van Kan, HJ; Wuthiekanun, V, 2007
)
0.65
"In the last decade, the relationship between drug dosing and treatment efficacy for life-threatening fungal infections has been clarified by application of pharmacodynamic principles to the study of antifungal agents."( Pharmacodynamic implications for use of antifungal agents.
Lewis, RE, 2007
)
0.34
" Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect."( Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing.
Denning, DW; Drusano, GL; Hope, WW; Keevil, B; Louie, A; Reed, P; Sharp, A; Walsh, TJ; Warn, PA, 2007
)
0.63
" It is widely recognized that the principles of pharmacokinetics and pharmacodynamics are critical to determining an adequate dose-response relationship."( CNS pharmacokinetics of antifungal agents.
Andes, D; Kethireddy, S, 2007
)
0.34
" Antifungal serum concentrations may aid in the determination of appropriate dosing in select circumstances."( Antifungal serum concentration monitoring: an update.
Drew, RH; Goodwin, ML, 2008
)
0.35
" Addition of flucytosine to fluconazole improved outcomes in each dosing cohort."( Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis.
Bozzette, SA; Haubrich, R; Larsen, RA; Leal, MA; Leedom, JM; McCutchan, JA; Milefchik, E; Tilles, JG, 2008
)
0.99
" The optimal dosing of AmB remains unclear."( Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings.
Dedicoat, M; Dlamini, S; Paul, N; Sloan, D, 2008
)
0.35
" Transfection of double suicide gene reduces the dosage of prodrugs required for killing cells."( [Killing effects of PWZL plasmid-mediated double suicide gene on human lens epithelium cells].
Wang, X; Wu, H; Yan, XR; Yu, HT; Zhang, Y, 2008
)
0.35
" At a dosage of 400 mg per day, fluconazole alone is much less rapidly fungicidal than amphotericin B and is associated with the development of secondary resistance."( Managing cryptococcosis in the immunocompromised host.
Dromer, F; Harrison, TS; Jarvis, JN; Lortholary, O, 2008
)
0.35
" Fluconazole at a dosage of 1200 mg per day is more fungicidal than at a dosage of 800 mg per day, but mortality rates remain unacceptably high."( Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi.
Harrison, TS; Hosseinipour, MC; Jackson, A; Jaffar, S; Jarvis, JN; Kamwendo, D; Kanyemba, C; Kenala, J; Namarika, D; Nussbaum, JC; Phulusa, J; van der Horst, CM, 2010
)
0.74
" The oral dosing of 5FC could be optimized by the use of a controlled-release (CR) formulation."( Clinical pharmacokinetics of oral controlled-release 5-fluorocytosine.
Bruce, H; Felton, LA; Pai, MP, 2010
)
0.36
" Survival benefit is dose dependent for both vector and 5-FC, and as few as 4 cycles of 5-FC dosing after Toca 511 therapy provides significant survival advantage."( Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Amundson, KK; Buckley, T; Burnett, R; Chen, CI; Daublebsky, V; Galvão da Silva, AP; Gruber, HE; Gunzburg, W; Hlavaty, J; Ibañez, CE; Jolly, DJ; Kasahara, N; Lin, AH; Lopez Espinoza, F; Martin, B; Ostertag, D; Perez, OD; Pettersson, PL; Robbins, JM; Valenta, DT, 2012
)
0.38
" In animal models, 12 days of 5-FC administration was superior to 6 days, but dosing beyond 12 days did not further enhance efficacy."( Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation.
Fuchs, BC; He, X; Kuroda, T; Lanuti, M; McGinn, CM; Schmitt, A; Supko, JG; Tanabe, KK; Yamada, S, 2012
)
0.38
" The optimal dosage of liposomal amphotericin B (LAmB) alone or in combination with flucytosine is not known."( Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients.
Felton, TW; Goodwin, J; Gregson, L; Harrison, TS; Hope, WW; Howard, SJ; Livermore, J; Neely, MN; O'Connor, L; Perfect, JR; Schwartz, JA; Sharp, AD, 2013
)
0.87
" Bridging studies suggested that a human dosage of LAmB 3 mg/kg/d resulted in a submaximal antifungal effect."( Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients.
Felton, TW; Goodwin, J; Gregson, L; Harrison, TS; Hope, WW; Howard, SJ; Livermore, J; Neely, MN; O'Connor, L; Perfect, JR; Schwartz, JA; Sharp, AD, 2013
)
0.64
"The antifungal drug, 5-fluorocytosine (FC), is marketed as a capsule (250 or 500 mg strength) instead of the preferred tablet dosage form."( Enabling tablet product development of 5-fluorocytosine through integrated crystal and particle engineering.
Perumalla, SR; Sun, CC, 2014
)
0.4
" Antimicrobial pharmacokinetic/pharmacodynamic (PK/PD) studies consider these variables and have been useful in drug development, optimizing dosing regimens, determining susceptibility breakpoints, and limiting toxicity of antifungal therapy."( Antifungal pharmacokinetics and pharmacodynamics.
Andes, DR; Lepak, AJ, 2014
)
0.4
" In addition, all MSCs were engineered to stably express luciferase gene making them suitable for quantitative imaging and dose-response relationship studies in animals."( Genetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme/prodrug systems.
Hatefi, A; Nouri, FS; Wang, X, 2015
)
0.42
" The nonsequential levels displayed good correlation, and no further monitoring or dosage adjustment was required."( Pharmacokinetics of flucytosine in a critically ill patient on continuous venovenous hemodiafiltration.
Adams, KK; Berard-Collins, C; Greene, RA; Lorenzo, MP; Rogers, RD, 2020
)
0.88
"Flucytosine dosed at 25 mg/kg of actual body weight every 12 hours during CVVHDF conferred therapeutic levels with no appreciable toxicities."( Pharmacokinetics of flucytosine in a critically ill patient on continuous venovenous hemodiafiltration.
Adams, KK; Berard-Collins, C; Greene, RA; Lorenzo, MP; Rogers, RD, 2020
)
2.32
" Flucytosine undergoes extensive renal elimination; however, optimal dosing in patients with renal impairment, or those requiring renal replacement therapy (RRT), is not well-established."( Therapeutic drug monitoring of flucytosine in a cardiac transplant patient receiving continuous veno-venous hemofiltration and intermittent hemodialysis: A case report.
Adamsick, ML; Bidell, MR; Elshaboury, RH; Gandhi, RG; Kotton, CN; Roberts, MB; Williams, KN, 2021
)
1.82
" Both of dosing of APS001F/5-FC before and after anti-PD-1 mAb in the combination dosing exhibited antitumor effects as well as prolonged survival over the nontreated control."( Potentiated antitumor effects of APS001F/5-FC combined with anti-PD-1 antibody in a CT26 syngeneic mouse model.
Matsumura, T; Nakamura, T; Seki, Y; Shimizu, H; Shioya, K; Taniguchi, S, 2021
)
0.62
" We show that this steep relationship can be explained by differences in the dose-response functions of 5-FC and cytosine."( Asymmetrical dose responses shape the evolutionary trade-off between antifungal resistance and nutrient use.
Alexander, EMM; Cisneros, AF; Després, PC; Dubé, AK; Gagné-Thivierge, C; Landry, CR; Sonigara, R, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
pyrimidoneA pyrimidine carrying one or more oxo substituents.
aminopyrimidineA member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
nucleoside analogueAn analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells.
pyrimidine antifungal drugAny pyrimidine antifungal agent that has been used for the treatment of fungal infections in humans or animals.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.08910.003245.467312,589.2998AID2517
phosphopantetheinyl transferaseBacillus subtilisPotency39.81070.141337.9142100.0000AID1490
AR proteinHomo sapiens (human)Potency1.02100.000221.22318,912.5098AID743036
EWS/FLI fusion proteinHomo sapiens (human)Potency15.93070.001310.157742.8575AID1259253; AID1259256
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency1.99530.28189.721235.4813AID2326
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency29.93490.168316.404067.0158AID720504
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency0.00520.004611.374133.4983AID624296
lamin isoform A-delta10Homo sapiens (human)Potency0.00080.891312.067628.1838AID1487
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency125.89206.309660.2008112.2020AID720707
Cellular tumor antigen p53Homo sapiens (human)Potency0.50740.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
heat shock protein 90Candida albicansEC50 (µMol)106.90370.12006.485533.8530AID2387; AID2400; AID2423
calcineurin A1, putativeCandida dubliniensis CD36EC50 (µMol)180.00004.66306.38108.0990AID2388
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Skn7pSaccharomyces cerevisiae (brewer's yeast)AbsAC40_uM1.83000.66005.269618.2300AID624258
HSP40, subfamily A [Plasmodium falciparum 3D7]Plasmodium falciparum 3D7AbsAC1000_uM1.51200.12904.116911.3160AID540271
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (184)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (60)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (40)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (866)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID405097Antimicrobial activity against Absidia sp. after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID574271Ratio of MIC for 10'8 cells/ml wild-type Candida albicans BF-1 to MIC for 10'7 cells/ml wild-type Candida albicans BF-1 grown as planktonic cells2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID284109Antifungal activity against Candida neoformans IM 052470 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID561429Antifungal activity against Candida lusitaniae CL31 by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID445509Antifungal activity against Candida albicans Berkout KCCM 50235 after 1 day by twofold broth dilution method2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Synthesis and antifungal activity of benzo[d]oxazole-4,7-diones.
AID356366Antifungal activity against Candida albicans ATCC 90028 by sphingolipid reversal assay in presence of 2.5 ug/mL dihydrosphingosine2003Journal of natural products, Aug, Volume: 66, Issue:8
Acetylenic acids inhibiting azole-resistant Candida albicans from Pentagonia gigantifolia.
AID283373Effect on aspartate aminotransferase level in intravenously dosed HIV associated cryptococcal meningitis patient after 2 weeks relative to baseline2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID519051Antifungal activity against Curvularia species after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID405104Antimicrobial activity against Rhizopus arrhizus assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID555594Antimicrobial activity against Trichosporon dermatis by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID405099Antimicrobial activity against Rhizomucor sp. after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID563708Antibacterial activity against Candida dubliniensis isolate SA109 harboring plasmid pNIM1 carrying GFP1T1 gene by broth microdilution method in presence of 25 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID1136880Antiyeast activity against Candida krusei 1-T assessed as total inhibition of fungal growth after 24 to 48 hrs by microdilution-colorimetric method1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Anticandidal activity of 5-fluorocytosine-peptide conjugates.
AID405094Antimicrobial activity against Rhizopus microsporus var. rhizopodiformis after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID1183070Antifungal activity against Candida norvegensis clinical isolate assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID563898Antibacterial activity against 5FC- resistant Candida dubliniensis isolate harboring plasmid p7276T3 carrying CdFCA1 gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID37707Antifungal activity against Aspergillus niger KCTC 12312000Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14
Synthesis and antifungal activities of 5/6-arylamino-4,7-dioxobenzothiazoles.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID292700Antifungal activity against Candida albicans Berkout KCCM 50235 after 1 day by 2-fold broth dilution method2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Synthesis and antifungal activity of 1H-indole-4,7-diones.
AID434893Antifungal activity against Candida tropicalis isolate 5 in RPMI 1640 medium by broth dilution susceptibility test2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin.
AID323598Antifungal activity against Candida tropicalis bloodstream isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
AID561433Antifungal activity against Candida lusitaniae CL48 by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID283382AUC in orally dosed HIV associated cryptococcal meningitis patient at 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID405276Antifungal activity against Sporothrix schenckii P3287 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID561430Antifungal activity against Candida lusitaniae CL32 by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID542331Fungicidal activity against Saccharomyces cerevisiae AY-10-R16 mutant after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Discovery of a small-molecule inhibitor of {beta}-1,6-glucan synthesis.
AID583474Antimicrobial activity against 5-fluorocytosine resistant and ura3 harboring Candida glabrata 66032u-FC1 harboring Fcy2L W291stop mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID519469Antimicrobial activity against Cryptococcus albidus by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID638560Antifungal activity against Aspergillus niger KCTC 1231 after 2 days by twofold broth dilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and antifungal activity of 6,7-bis(arylthio)-quinazoline-5,8-diones and furo[2,3-f]quinazolin-5-ols.
AID583483Antimicrobial activity against 5-fluorocytosine resistant Candida glabrata isolate 20408.055 harboring Fur1 G210D mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID537736Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID283351Effect on neutrophils level in orally dosed HIV associated cryptococcal meningitis patient relative to control2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID535684Antibacterial activity against Cryptococcus gattii after 72 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID519054Antifungal activity against Penicillium marneffei after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID263334Antifungal activity against Cryptococcus neoformans KCCM 505642006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
Synthesis and antifungal activity of 6-hydroxycinnolines.
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID555574Antimicrobial activity against Candida rugosa by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID47311Cytotoxicity was determined in CEM cells, relative to RVT2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.
AID638559Antifungal activity against Cryptococcus neoformans KCCM 50564 after 1 day by twofold broth dilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and antifungal activity of 6,7-bis(arylthio)-quinazoline-5,8-diones and furo[2,3-f]quinazolin-5-ols.
AID432803Antifungal activity against Sporothrix albicans after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID555576Antimicrobial activity against Candida pelliculosa by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID283360Effect on creatinine clearance in intravenously dosed HIV associated cryptococcal meningitis patient relative to control2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID405063Antifungal activity against Sporothrix schenckii P3287 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID445508Antifungal activity against Candida tropicalis Berkout KCCM 50662 after 1 day by twofold broth dilution method2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Synthesis and antifungal activity of benzo[d]oxazole-4,7-diones.
AID568479Antifungal activity against Cryptococcus neoformans KCCM 50564 after 2 days by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and antifungal activity of furo[2,3-f]quinolin-5-ols.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID432800Antifungal activity against Sporothrix schenckii after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID561437Antifungal activity against Candida lusitaniae CL216 by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID563917Antibacterial activity against Candida dubliniensis isolate p6785 of Cd25 fingerprint group 2 and ITS genotype 3 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID1183062Antifungal activity against Candida dubliniensis ATCC MYA-646 assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID519053Antifungal activity against Paecilomyces variotii after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID583485Antimicrobial activity against 5-fluorocytosine resistant Candida glabrata isolate TE34-75 harboring FcY2J 1384F mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID405064Antifungal activity against Sporothrix schenckii P3287 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID555585Antimicrobial activity against Dipodascus capitatus by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID563703Antibacterial activity against Candida dubliniensis harboring plasmid p7276 by broth microdilution method in presence of 30 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID405018Antifungal activity against Sporothrix schenckii P20825 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID405223Antimicrobial activity against Blastoschizomyces capitatus IHEM 5666 isolate infected OF1 mouse blastoschizomycosis model assessed as kidney microbial count at 60 mg/kg/day, po for 6 days administered 1 hr before microbial challenge2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Combined therapies in a murine model of blastoschizomycosis.
AID283375Effect on creatinine clearance in intravenously dosed HIV associated cryptococcal meningitis patient after 2 weeks relative to baseline2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID405010Antifungal activity against Sporothrix schenckii P0019 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID520620Antifungal activity against Candida metapsilosis by microdilution AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain.
AID519049Antifungal activity against Candida tropicalis after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID583477Antimicrobial activity against 5-fluorocytosine resistant and ura3 harboring Candida glabrata 66032u-FC3 harboring Fcy1 H59D mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID563712Antibacterial activity against 5FC- susceptible Candida dubliniensis isolate SA109T1 harboring plasmid pNIM1 carrying CdFCA1 gene by broth microdilution method in presence of 25 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID278194Antifungal activity against flucytosine-resistant Cryptococcus neoformans 550 at 64 ug/ml after 72 hrs by time-kill method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID306708Antifungal activity against Candida tropicalis Berkout KCCM 50662 after 1 day by broth dilution method2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Synthesis and antifungal activity of 6-arylamino-phthalazine-5,8-diones and 6,7-bis(arylthio)-phthalazine-5,8-diones.
AID566879Antifungal activity against Candida glabrata by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID278197Antifungal activity against flucytosine-resistant Cryptococcus neoformans 98.1121 at 64 ug/ml after 72 hrs by time-kill method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID245521Minimum inhibitory concentration was measured against Candida krusei ATCC 749 using modified Sabouraud dextrose broth; (a)2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Synthesis and antifungal activity of noble 5-arylamino- and 6-arylthio-4,7-dioxobenzoselenazoles.
AID278158Antifungal activity against flucytosine-resistant Cryptococcus neoformans 98.1121 by checkerboard method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID405055Antifungal activity against Sporothrix schenckii PJRC002 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID555584Antimicrobial activity against Candida zeylanoides by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID574270Antifungal activity against 48 hrs cultures of 10'7 cells/ml biofilm-derived Candida albicans BF-1 planktonic cells hrs by XTT reduction method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID405066Antifungal activity against Candida krusei ATCC 6258 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1136543Antifungal activity against Aspergillus niger ATCC 1004 at pH 7 after 5 days in absence of 10% beef serum1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Antifungal properties of 2-bromo-3-fluorosuccinic acid esters and related compounds.
AID563719Antibacterial activity against Candida dubliniensis isolate harboring plasmid p7276 carrying GFP1T1 gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID434899Antifungal activity against Candida tropicalis ATCC 750 in RPMI 1640 medium by broth dilution susceptibility test2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin.
AID155299Cytotoxicity was determined in PBM cells, relative to RVT2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.
AID563902Antibacterial activity against Candida dubliniensis isolate SA109 by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID701456Antifungal activity against Aspergillus flavus2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
The biology and chemistry of antifungal agents: a review.
AID565397Antifungal activity against Rhizopus microsporus FMR 3542 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID283365Effect on hemoglobin level in intravenously dosed HIV associated cryptococcal meningitis patient after 2 weeks relative to baseline2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID535392Antifungal activity against Aspergillus fumigatus at pH 7.0 by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus.
AID1732072Antifungal activity against Aspergillus versicolor SRX7729182 STG-25G assessed as reduction in fungal growth at 0.1 to 3.5 mM measured for 24 days by drop dilution assay relative to control2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel N
AID425723Antimicrobial activity against Balamuthia mandrillaris ATCC 50209 infected in HBMEC assessed as inhibition of amoeba-induced cytopathogenicity at 10 ug/mL after 24 hrs by LDH release assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Effect of antimicrobial compounds on Balamuthia mandrillaris encystment and human brain microvascular endothelial cell cytopathogenicity.
AID583484Antimicrobial activity against 5-fluorocytosine resistant Candida glabrata isolate TE34-78 harboring Fcr1 L136R mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID405059Antifungal activity against Sporothrix schenckii P14036 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID555597Antimicrobial activity against Ustilago spp by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID555580Antimicrobial activity against Candida inconspicua by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1183068Antifungal activity against Candida krusei ATCC 6258 assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID405039Antifungal activity against Sporothrix schenckii P10012 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID535395Antifungal activity against flucytosine-susceptible Aspergillus fumigatus isolate AZN 58 infected in CD-1 mouse assessed as prolongation of survival at 200 mg/kg administered every 6 hrs2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus.
AID555590Antimicrobial activity against Trichosporon asahii by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID583476Antimicrobial activity against 5-fluorocytosine resistant and ura3 harboring Candida glabrata 66032u-FC10 harboring Fcy2L Q396stop mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID563920Antibacterial activity against Candida dubliniensis isolate Eg203 of Cd25 fingerprint group 1 and ITS genotype 1 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID510310Antimicrobial activity against flucytosine, azole, and caspofungin resistant Candida glabrata bloodstream isolate 4 harboring FKS2 T1988C mutation and overexpressing CDR1 and CDR2 genes serially obtained from hematopoietic stem cell transplant recipient b2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.
AID278142Antifungal activity against flucytosine-resistant Cryptococcus neoformans 98.0176 by checkerboard method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID555591Antimicrobial activity against Rhodotorula mucilaginosa by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID565553Antifungal activity against Rhizopus microsporus UTHSC 03-1802 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID405058Antifungal activity against Sporothrix schenckii P14036 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID519057Antifungal activity against Candida glabrata assessed as susceptible isolates after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID519467Antimicrobial activity against Cryptococcus neoformans var. grubii obtained from non-AIDS patient by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID405013Antifungal activity against Sporothrix schenckii PSSA81 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID425722Antimicrobial activity against Balamuthia mandrillaris ATCC 50209 infected in HBMEC assessed as inhibition of amoeba-induced cytopathogenicity at 5 ug/mL after 24 hrs by LDH release assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Effect of antimicrobial compounds on Balamuthia mandrillaris encystment and human brain microvascular endothelial cell cytopathogenicity.
AID48810Tested for antifungal activity against 5-FC resistant strain Candida tropicalis CIP 1745-88 after 48 hr incubation2001Bioorganic & medicinal chemistry letters, Dec-03, Volume: 11, Issue:23
Stereoselective synthesis of 7 alpha- and 7 beta-aminocholestanol as potent fungicidal drugs.
AID672347Antifungal activity against Aspergillus flavus KCCM 11899 after 2 days2012Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15
Synthesis, antitubercular and antimicrobial evaluation of 3-(4-chlorophenyl)-4-substituted pyrazole derivatives.
AID555579Antimicrobial activity against Candida intermedia by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID563921Antibacterial activity against Candida dubliniensis isolate SA115 of Cd25 fingerprint group 1 and ITS genotype 1 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID566887Antifungal activity against Aspergillus terreus by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID555588Antimicrobial activity against Galactomyces geotrichum by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID583482Antimicrobial activity against 5-fluorocytosine resistant Candida glabrata isolate 20251.021 harboring Fcy1 T84L mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID283380Volume of distribution in intravenously dosed HIV associated cryptococcal meningitis patient normalized to weight2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID283378Volume of distribution in orally dosed HIV associated cryptococcal meningitis patient normalized to weight2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID284107Antifungal activity against Candida neoformans IM 031706 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID405105Antimicrobial activity against Rhizopus microsporus var. rhizopodiformis assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID561428Antifungal activity against Candida lusitaniae CL29 by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID555598Antimicrobial activity against Rhodotorula glutinis by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID405021Antifungal activity against Sporothrix schenckii P30019 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID405033Antifungal activity against Sporothrix schenckii PSCC1 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID283357Effect on aspartate aminotransferase level in orally dosed HIV associated cryptococcal meningitis patient relative to control2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID306711Antifungal activity against Aspergillus niger KCTC 1231 after 2 days by broth dilution method2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Synthesis and antifungal activity of 6-arylamino-phthalazine-5,8-diones and 6,7-bis(arylthio)-phthalazine-5,8-diones.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID555586Antimicrobial activity against Saccharomyces cerevisiae by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID546072Antifungal activity against Candida glabrata isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID425716Antimicrobial activity against Balamuthia mandrillaris ATCC 50209 infected in HBMEC assessed as inhibition of encystment at 5 ug/mL after 7 days2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Effect of antimicrobial compounds on Balamuthia mandrillaris encystment and human brain microvascular endothelial cell cytopathogenicity.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID535399Half life in human2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus.
AID519055Antifungal activity against Penicillium sp. after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID405077Antifungal activity against Sporothrix schenckii isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID671986Induction of apoptosis in human HepG2 cells assessed as morphological nuclear changes by Hoechst33342-staining based high content screening assay2012Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
Synthesis and cytotoxic activity of 4-N-carboxybutyl-5-fluorocytosyl-Arg-Gln-Trp-Arg-Arg-Trp-Trp-Gln-Arg-NH₂.
AID561434Antifungal activity against Candida lusitaniae CL119 by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID1136550Antifungal activity against Mucor mucedo ATCC 7941 at <100 ug/ml at pH 5.6 after 5 days in presence of 10% beef serum1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Antifungal properties of 2-bromo-3-fluorosuccinic acid esters and related compounds.
AID445511Antifungal activity against Cryptococcus neoformans KCCM 50564 after 1 day by twofold broth dilution method2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Synthesis and antifungal activity of benzo[d]oxazole-4,7-diones.
AID546076Antifungal activity against Candida rugosa isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID561422Antifungal activity against fcy1(1-119)-deficient Candida lusitaniae by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID278155Antifungal activity against flucytosine-resistant Cryptococcus neoformans 550 by checkerboard method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID519047Antifungal activity against Candida krusei after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID546071Antifungal activity against Clavispora lusitaniae isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID555583Antimicrobial activity against Candida pintolopesii by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID563918Antibacterial activity against Candida dubliniensis isolate p7276 of Cd25 fingerprint group 2 and ITS genotype 3 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID405092Antimicrobial activity against Rhizopus sp. after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID519468Antimicrobial activity against Cryptococcus gattii by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID263332Antifungal activity against Candida tropicalis KCCM 506622006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
Synthesis and antifungal activity of 6-hydroxycinnolines.
AID555566Antimicrobial activity against Candida albicans by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID283366Effect on neutrophils level in orally dosed HIV associated cryptococcal meningitis patient after 2 weeks relative to baseline2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID405023Antifungal activity against Sporothrix schenckii P30019 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1136565Antifungal activity against Candida albicans ATCC 10231 at pH 5.6 after 5 days in presence of 10% beef serum1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Antifungal properties of 2-bromo-3-fluorosuccinic acid esters and related compounds.
AID583468Antimicrobial activity against 5-fluorocytosine resistant Candida glabrata 66032-FC3 harboring Fur1 G71V mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID555575Antimicrobial activity against Candida famata by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID245537In vitro minimum inhibitory concentration against Aspergillus niger KCTC 1231 strain at 37 degree C after 2 day of treatment2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Synthesis and antifungal activity of 5-arylamino-4,7-dioxobenzo[b]thiophenes.
AID535687Antibacterial activity against Cryptococcus neoformans serotype D after 72 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID405076Antifungal activity against Sporothrix schenckii isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID278146Antifungal activity against flucytosine-resistant Cryptococcus neoformans 98.0673 by checkerboard method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID561435Antifungal activity against Candida lusitaniae CL128 by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID563707Antibacterial activity against Candida dubliniensis isolate SA109 harboring plasmid pNIM1 carrying GFP1T2 gene by broth microdilution method in presence of 25 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID534350Antifungal activity against fsk1 gene deficient Candida albicans2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene.
AID555587Antimicrobial activity against Yarrowia lipolytica by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID526736Antifungal activity against Aspergillus niger KCTC 1231 after 2 days2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Synthesis and antifungal activity of benzofuran-5-ols.
AID546073Antifungal activity against Candida tropicalis isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID561426Antifungal activity against Candida lusitaniae CL38-5 expressing FCY21 gene by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID565399Antifungal activity against Rhizopus microsporus IHEM 18821 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID405108Antimicrobial activity against Mucor circinelloides assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID566891Antifungal activity against Exophiala xenobiotica by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID434895Antifungal activity against Candida tropicalis isolate 7 in RPMI 1640 medium by broth dilution susceptibility test2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin.
AID519046Antifungal activity against Candida glabrata after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID563935Antibacterial activity against Candida dubliniensis isolate harboring plasmid p7276 carrying GFP1T1 gene by broth microdilution method in presence of 30 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID574255Antifungal activity against 48 hrs cultures of 10'7 cells/ml wild-type Candida albicans BF-1 biofilms by XTT reduction assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID519465Antimicrobial activity against Cryptococcus neoformans var. grubii clinical isolate by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID555573Antimicrobial activity against Candida kefyr by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID1136569Antifungal activity against Candida albicans ATCC 10231 at pH 7 after 5 days in presence of 10% beef serum1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Antifungal properties of 2-bromo-3-fluorosuccinic acid esters and related compounds.
AID555571Antimicrobial activity against Candida guilliermondii by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID278148Antifungal activity against flucytosine-resistant Cryptococcus neoformans 98.1121 by checkerboard method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID535686Antibacterial activity against Cryptococcus neoformans serotype A after 72 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID521787Antifungal activity against Candida albicans after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID434897Antifungal activity against Candida tropicalis isolate 13 in RPMI 1640 medium by broth dilution susceptibility test2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin.
AID685358Antifungal activity against Candida albicans after 48 hrs by broth microdilution method2012European journal of medicinal chemistry, Oct, Volume: 56Micelles catalyzed chemo- and regio-selective one pot and one step synthesis of 2,3,5,6-tetrakis(alkyl and arylsulfanyl)-1,4-benzoquinones and 2,5-diaminosubstituted-1,4-benzoquinones "In-Water" and their biological evaluation as antibacterial and antifun
AID574263Antifungal activity against 24 hrs cultures of 10'7 cells/ml Candida albicans ATCC 90028 biofilms by XTT reduction method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID519050Antifungal activity against Aspergillus sp. after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID323595Antifungal activity against Candida glabrata bloodstream isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID519064Antifungal activity against Candida parapsilosis assessed as resistant isolates after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID563895Antibacterial activity against 5FC- susceptible Candida dubliniensis isolate SA113T1 harboring plasmid pNIM1 carrying CdFCA1 gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID1238923Antifungal activity against Candida parapsilosis ATCC 90018 WTBF-88 by microbroth dilution method2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Synthesis and antifungal evaluation of head-to-head and head-to-tail bisamidine compounds.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID336473Antimicrobial activity against Candida albicans by standard microdilution broth method2002Journal of natural products, Oct, Volume: 65, Issue:10
New bioactive peroxides from marine sponges of the family plakiniidae.
AID574254Antifungal activity against 48 hrs cultures of 10'7 cells/ml Candida albicans ATCC 90028 biofilms by XTT reduction assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID405046Antifungal activity against Sporothrix schenckii SSA29 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID278151Antifungal activity against flucytosine-resistant Cryptococcus neoformans 533 by checkerboard method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID283364Effect on hemoglobin level in orally dosed HIV associated cryptococcal meningitis patient after 2 weeks relative to baseline2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID566884Antifungal activity against Aspergillus flavus by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID555572Antimicrobial activity against Candida lusitaniae by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1366580Antifungal activity against Aspergillus fumigatus after 24 hrs by micro broth dilution method2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Novel potentially antifungal hybrids of 5-flucytosine and fluconazole: Design, synthesis and bioactive evaluation.
AID283383AUC in intravenously dosed HIV associated cryptococcal meningitis patient at 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID50149Antifungal activity against Candida krusei ATCC 7492000Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14
Synthesis and antifungal activities of 5/6-arylamino-4,7-dioxobenzothiazoles.
AID405102Antimicrobial activity against Apophysomyces elegans after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID555567Antimicrobial activity against Candida parapsilosis by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID701473Antifungal activity against Aspergillus niger2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
The biology and chemistry of antifungal agents: a review.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID519059Antifungal activity against Candida parapsilosis assessed as susceptible isolates after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID417267Antifungal activity against Candida albicans isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing.
AID563914Antibacterial activity against Candida dubliniensis isolate Eg201 of Cd25 fingerprint group 3 and ITS genotype 4 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID263335Antifungal activity against Aspergillus niger KCTC 12312006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
Synthesis and antifungal activity of 6-hydroxycinnolines.
AID155572In vitro antiviral activity against Para influenza virus type 3 strain C243 was evaluated in african green monkey kidney1985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates.
AID1183065Antifungal activity against Candida guilliermondii ATCC 6260 assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID574062Antifungal activity against 10'5 cells/ml wild-type Candida albicans BF-1 by EUCAST method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID741611Antifungal activity against Aspergillus flavus KCCM 11899 after 2 days by two fold broth dilution method2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Synthesis and antifungal evaluation of 7-arylamino-5,8-dioxo-5,8-dihydroisoquinoline-4-carboxylates.
AID278153Antifungal activity against flucytosine-resistant Cryptococcus neoformans 18476 by checkerboard method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID701458Antifungal activity against Candida albicans2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
The biology and chemistry of antifungal agents: a review.
AID278193Antifungal activity against flucytosine-resistant Cryptococcus neoformans 18476 at 64 ug/ml after 72 hrs by time-kill method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID563915Antibacterial activity against Candida dubliniensis isolate Eg200 of Cd25 fingerprint group 3 and ITS genotype 4 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID405095Antimicrobial activity against Rhizopus microsporus var. rhizopodiformis after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID535685Antibacterial activity against Cryptococcus neoformans after 72 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID542332Fungicidal activity against Saccharomyces cerevisiae CT-1a mutant after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Discovery of a small-molecule inhibitor of {beta}-1,6-glucan synthesis.
AID278159Antifungal activity against flucytosine-resistant Cryptococcus neoformans 276 by checkerboard method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID519048Antifungal activity against Candida parapsilosis after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID284103Antifungal activity against Candida neoformans IM 983036 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID1732071Antifungal activity against Aspergillus-creber SRX7729180 STG-57 assessed as reduction in fungal growth at 0.1 to 3.5 mM measured for 24 days by drop dilution assay relative to control2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel N
AID519061Antifungal activity against Candida albicans assessed as resistant isolates after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID535394Antifungal activity against flucytosine-susceptible Aspergillus fumigatus isolate AZN 58 infected in CD-1 mouse assessed as prolongation of survival at 100 mg/kg administered every 6 hrs2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus.
AID546068Antifungal activity against Candida albicans isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID284105Antifungal activity against Candida neoformans IM 972751 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID323594Antifungal activity against Candida albicans bloodstream isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
AID306707Antifungal activity against Candida albicans Berkout KCCM 50235 after 1 day by broth dilution method2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Synthesis and antifungal activity of 6-arylamino-phthalazine-5,8-diones and 6,7-bis(arylthio)-phthalazine-5,8-diones.
AID519464Antimicrobial activity against Cryptococcus neoformans var. grubii by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID563720Antibacterial activity against Candida dubliniensis isolate SA109 harboring plasmid pNIM1 carrying GFP1T2 gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID565550Antifungal activity against Rhizopus microsporus IHEM 13311 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID510311Antimicrobial activity against flucytosine, azole, and caspofungin resistant Candida glabrata bloodstream isolate 5 harboring FKS2 T1988C mutation and overexpressing CDR1 and CDR2 genes serially obtained from hematopoietic stem cell transplant recipient b2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.
AID555569Antimicrobial activity against Candida glabrata by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID563931Antibacterial activity against 5FC- susceptible Candida dubliniensis isolate SA113T1 harboring plasmid pNIM1 carrying CdFCA1 gene by broth microdilution method in presence of 30 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID405029Antifungal activity against Sporothrix schenckii MRSS4 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID535393Antifungal activity against Aspergillus fumigatus at pH 5.0 by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus.
AID405208Antimicrobial activity against Blastoschizomyces capitatus IHEM 16105 isolate infected OF1 mouse blastoschizomycosis model assessed as kidney microbial count per gram of tissue at 60 mg/kg/day, po for 6 days administered 1 hr before microbial challenge2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Combined therapies in a murine model of blastoschizomycosis.
AID520619Antifungal activity against Candida orthopsilosis by microdilution AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain.
AID542334Fungicidal activity against Saccharomyces cerevisiae AY-10 transformed with empty vector pRS416 after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Discovery of a small-molecule inhibitor of {beta}-1,6-glucan synthesis.
AID405206Antimicrobial activity against Blastoschizomyces capitatus IHEM 16105 isolate infected OF1 mouse blastoschizomycosis model assessed as liver microbial count per gram of tissue at 60 mg/kg/day, po for 6 days administered 1 hr before microbial challenge2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Combined therapies in a murine model of blastoschizomycosis.
AID519282Antifungal activity against Candida krusei ATCC 6258 by CLSI M27-A2 microdilution method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.
AID565404Antifungal activity against Rhizopus microsporus IHEM 5234 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID405413Antimicrobial activity against Blastoschizomyces capitatus IHEM 16105 isolate infected OF1 mouse blastoschizomycosis model assessed as spleen microbial count per gram of tissue at 60 mg/kg/day, po for 6 days administered 1 hr before microbial challenge2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Combined therapies in a murine model of blastoschizomycosis.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID526733Antifungal activity against Candida tropicalis KCCM 50662 after 1 day2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Synthesis and antifungal activity of benzofuran-5-ols.
AID574059Antifungal activity against 10'3 cells/ml Candida albicans ATCC 90028 by NCCLS method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID741613Antifungal activity against Cryptococcus neoformans KCCM 50564 after 1 day by two fold broth dilution method2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Synthesis and antifungal evaluation of 7-arylamino-5,8-dioxo-5,8-dihydroisoquinoline-4-carboxylates.
AID405106Antimicrobial activity against Rhizopus microsporus var. microsporus assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID638556Antifungal activity against Candida albicans Berkout KCCM 50235 after 1 day by twofold broth dilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and antifungal activity of 6,7-bis(arylthio)-quinazoline-5,8-diones and furo[2,3-f]quinazolin-5-ols.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID671984Cytotoxicity in human HepG2 cells assessed as alteration of mitochondrial membrane potential by TMRM-fluorescence based high content screening assay2012Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
Synthesis and cytotoxic activity of 4-N-carboxybutyl-5-fluorocytosyl-Arg-Gln-Trp-Arg-Arg-Trp-Trp-Gln-Arg-NH₂.
AID283353Effect on platelet count in orally dosed HIV associated cryptococcal meningitis patient relative to control2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID412144Antifungal activity against Candida albicans KCCM 50235 after 1 day2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Synthesis and antifungal activity of 1H-pyrrolo[3,2-g]quinoline-4,9-diones and 4,9-dioxo-4,9-dihydro-1H-benzo[f]indoles.
AID563919Antibacterial activity against Candida dubliniensis isolate Eg206 of Cd25 fingerprint group 1 and ITS genotype 1 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID566881Antifungal activity against Candida guilliermondii by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID583469Antimicrobial activity against 5-fluorocytosine resistant Candida glabrata 66032 assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID278192Antifungal activity against flucytosine-resistant Cryptococcus neoformans 98.0176 at 64 ug/ml after 72 hrs by time-kill method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID535400Antifungal activity against flucytosine-resistant Aspergillus fumigatus isolate AZN 58 infected in CD-1 mouse at 100 mg/kg administered every 6 hrs2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus.
AID563932Antibacterial activity against Candida dubliniensis isolate SA113 harboring plasmid pNIM1 carrying GFP1T1 gene by broth microdilution method in presence of 30 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID278178Antifungal activity against flucytosine-resistant Cryptococcus neoformans 98.1121 by Etest method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID565401Antifungal activity against Rhizopus microsporus IHEM 9503 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID555602Antimicrobial activity against Trichosporon spp. by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID323070Antifungal activity against Cryptococcus neoformans IM 983036 by micro-broth dilution method2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID432799Antifungal activity against Sporothrix brasiliensis after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID278200Antifungal activity against flucytosine-resistant Cryptococcus neoformans 533 at 64 ug/ml after 72 hrs by time-kill method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID555599Antimicrobial activity against Cryptococcus laurentii by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID409960Inhibition of bovine brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID306709Antifungal activity against Candida krusei Berkout KCCM 11655 after 1 day by broth dilution method2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Synthesis and antifungal activity of 6-arylamino-phthalazine-5,8-diones and 6,7-bis(arylthio)-phthalazine-5,8-diones.
AID405017Antifungal activity against Sporothrix schenckii P25013 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID563901Antibacterial activity against Candida dubliniensis harboring plasmid p7276 by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID1183066Antifungal activity against Candida inconspicua clinical isolate assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID638566Antifungal activity against Aspergillus niger KCTC 1231 after 2 days by two fold broth dilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and antifungal evaluation of pyrido[1,2-a]indole-1,4-diones and benzo[f]pyrido[1,2-a]indole-6,11-diones.
AID86027Antiviral activity against Herpes simplex virus -1 strain KOS was evaluated in african green monkey kidney1985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates.
AID405034Antifungal activity against Sporothrix schenckii PSCC1 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID45472In vitro antifungal activity against Candida albicans ATCC 10231 was measured2003Bioorganic & medicinal chemistry letters, Jan-06, Volume: 13, Issue:1
Synthesis and antifungal activity of 2,5-disubstituted-6-arylamino-4,7-benzimidazolediones.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID283367Effect on neutrophils level in intravenously dosed HIV associated cryptococcal meningitis patient after 2 weeks relative to baseline2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID555581Antimicrobial activity against Candida metapsilosis by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID535690Antibacterial activity against Cryptococcus gattii serotype C after 72 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID682603Antifungal activity against Cryptococcus neoformans after 72 hrs by broth microdilution method2012European journal of medicinal chemistry, Oct, Volume: 56Micelles catalyzed chemo- and regio-selective one pot and one step synthesis of 2,3,5,6-tetrakis(alkyl and arylsulfanyl)-1,4-benzoquinones and 2,5-diaminosubstituted-1,4-benzoquinones "In-Water" and their biological evaluation as antibacterial and antifun
AID1183063Antifungal activity against Candida famata VKMY-9 assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID542335Fungicidal activity against Saccharomyces cerevisiae AY-10 transformed with pRS416-13 carrying ADP1 gene after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Discovery of a small-molecule inhibitor of {beta}-1,6-glucan synthesis.
AID535689Antibacterial activity against Cryptococcus gattii serotype B after 72 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID565402Antifungal activity against Rhizopus microsporus IHEM 10123 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID432801Antifungal activity against Sporothrix globosa after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID1156865Antimicrobial activity against Sporothrix schenckii after 72 hrs by microbroth dilution method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis of 2,3,6-trideoxy sugar triazole hybrids as potential new broad spectrum antimicrobial agents.
AID555589Antimicrobial activity against Cryptococcus neoformans var. neoformans by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID555596Antimicrobial activity against Cryptococcus albidus by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID405096Antimicrobial activity against Mucor sp. after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID555582Antimicrobial activity against Candida orthopsilosis by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID638558Antifungal activity against Candida krusei Berkout KCCM 11655 after 1 day by twofold broth dilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and antifungal activity of 6,7-bis(arylthio)-quinazoline-5,8-diones and furo[2,3-f]quinazolin-5-ols.
AID405075Antifungal activity against Sporothrix schenckii isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID555593Antimicrobial activity against Trichosporon ovoides by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID434894Antifungal activity against Candida tropicalis isolate 6 in RPMI 1640 medium by broth dilution susceptibility test2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin.
AID405110Antimicrobial activity against Absidia sp. assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID542329Fungicidal activity against Saccharomyces cerevisiae AY-10-R11 mutant after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Discovery of a small-molecule inhibitor of {beta}-1,6-glucan synthesis.
AID405185Antimicrobial activity against Blastoschizomyces capitatus IHEM 16105 isolate by microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Combined therapies in a murine model of blastoschizomycosis.
AID555601Antimicrobial activity against Trichosporon mycotoxinivorans by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID434898Antifungal activity against Candida tropicalis isolate 15 in RPMI 1640 medium by broth dilution susceptibility test2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin.
AID405057Antifungal activity against Sporothrix schenckii P14036 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID583478Antimicrobial activity against 5-fluorocytosine resistant and ura3 harboring Candida glabrata 66032u assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID200310Tested for antifungal activity against Saccharomyces cerevisiae ATCC 28 383 after 48 hr incubation2001Bioorganic & medicinal chemistry letters, Dec-03, Volume: 11, Issue:23
Stereoselective synthesis of 7 alpha- and 7 beta-aminocholestanol as potent fungicidal drugs.
AID583471Antimicrobial activity against 5-fluorocytosine resistant Candida glabrata 66032-FC6 harboring Fcy1 G11D mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID519470Antimicrobial activity against Cryptococcus albidosimilis by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID323597Antifungal activity against Candida parapsilosis bloodstream isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
AID405050Antifungal activity against Sporothrix schenckii P26187 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID682978Antifungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by broth microdilution method2012European journal of medicinal chemistry, Oct, Volume: 56Micelles catalyzed chemo- and regio-selective one pot and one step synthesis of 2,3,5,6-tetrakis(alkyl and arylsulfanyl)-1,4-benzoquinones and 2,5-diaminosubstituted-1,4-benzoquinones "In-Water" and their biological evaluation as antibacterial and antifun
AID537733Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID283379Clearance in intravenously dosed HIV associated cryptococcal meningitis patient2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID245578Minimum inhibitory concentration was measured against Aspergillus flavus KCCM 11899 using modified Sabouraud dextrose broth; (a)2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Synthesis and antifungal activity of noble 5-arylamino- and 6-arylthio-4,7-dioxobenzoselenazoles.
AID566888Antifungal activity against Cladophialophora carrionii by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID519285Antifungal activity against Candida parapsilosis ATCC 22019 by CLSI M27-A2 microdilution method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.
AID519466Antimicrobial activity against Cryptococcus neoformans var. grubii obtained from AIDS patient by broth microdilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.
AID563897Antibacterial activity against 5FC- susceptible Candida dubliniensis isolate SA109T1 harboring plasmid pNIM1 carrying CdFCA1 gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID671983Cytotoxicity against human HepG2 cells at 4 to 10 mM after 24 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
Synthesis and cytotoxic activity of 4-N-carboxybutyl-5-fluorocytosyl-Arg-Gln-Trp-Arg-Arg-Trp-Trp-Gln-Arg-NH₂.
AID359612Antifungal activity against Candida albicans 44506 assessed as inhibition of U-14C-glucose incorporation into TCA precipitable material after 1 hr1992Journal of natural products, Nov, Volume: 55, Issue:11
Antifungal activity of meridine, a natural product from the marine sponge Corticium sp.
AID323599Antifungal activity against Candida sp. bloodstream isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
AID356442Antifungal activity against Candida albicans ATCC 90028 after 24 to 48 hrs by NCCLS method2003Journal of natural products, Aug, Volume: 66, Issue:8
Acetylenic acids inhibiting azole-resistant Candida albicans from Pentagonia gigantifolia.
AID283371Effect on alanine transferase level in intravenously dosed HIV associated cryptococcal meningitis patient after 2 weeks relative to baseline2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID412147Antifungal activity against Aspergillus niger KCTC 1231 after 2 days2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Synthesis and antifungal activity of 1H-pyrrolo[3,2-g]quinoline-4,9-diones and 4,9-dioxo-4,9-dihydro-1H-benzo[f]indoles.
AID563702Antibacterial activity against 5FC- resistant Candida dubliniensis isolate harboring plasmid p7276T1 carrying CdFCA1 gene by broth microdilution method in presence of 30 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1732076Antifungal activity against Cladosporium-parahalotolerans SRX7729188 STG-93B assessed as reduction in fungal growth at 0.1 to 3.5 mM measured for 24 days by drop dilution assay relative to control2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel N
AID563706Antibacterial activity against Candida dubliniensis isolate harboring plasmid p7276 carrying GFP1T1 gene by broth microdilution method in presence of 25 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID292701Antifungal activity against Candida tropicalis Berkout KCCM 50662 after 1 day by 2-fold broth dilution method2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Synthesis and antifungal activity of 1H-indole-4,7-diones.
AID1136552Antifungal activity against Mucor mucedo ATCC 7941 at <100 ug/ml at pH 7 after 5 days in absence of 10% beef serum1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Antifungal properties of 2-bromo-3-fluorosuccinic acid esters and related compounds.
AID526735Antifungal activity against Cryptococcus neoformans KCCM 50564 after 1 day2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Synthesis and antifungal activity of benzofuran-5-ols.
AID48926Tested for antifungal activity against Candida albicans CIP 1180-79 after 48 h incubation2001Bioorganic & medicinal chemistry letters, Dec-03, Volume: 11, Issue:23
Stereoselective synthesis of 7 alpha- and 7 beta-aminocholestanol as potent fungicidal drugs.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID405041Antifungal activity against Sporothrix schenckii P10012 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID574248Antifungal activity against 10'7 cells/ml Candida albicans ATCC 90028 planktonic cells by XTT reduction assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID563928Antibacterial activity against 5FC-susceptible Candida dubliniensis by NCCLS M27-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID563929Antibacterial activity against Candida albicans by EUCAST method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID278180Antifungal activity against flucytosine-resistant Cryptococcus neoformans 280 by Etest method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID278195Antifungal activity against flucytosine-resistant Cryptococcus neoformans 98.0673 at 64 ug/ml after 72 hrs by time-kill method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID1136548Antifungal activity against Mucor mucedo ATCC 7941 at <100 ug/ml at pH 5.6 after 5 days in absence of 10% beef serum1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Antifungal properties of 2-bromo-3-fluorosuccinic acid esters and related compounds.
AID405190Antimicrobial activity against Blastoschizomyces capitatus IHEM 16105 isolate infected OF1 mouse blastoschizomycosis model assessed as mean survival time at 60 mg/kg/day, po for 6 days administered 1 hr before microbial challenge2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Combined therapies in a murine model of blastoschizomycosis.
AID563701Antibacterial activity against 5FC- resistant Candida dubliniensis isolate harboring plasmid p7276T2 carrying CdFCA1 gene by broth microdilution method in presence of 30 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID278385Antifungal activity against Candida lusitaniae 6936 revertant fcy1delta::[FCY1-URA3] by microdilution assay2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance.
AID574262Antifungal activity against 48 hrs cultures of 10'7 cells/ml Candida albicans BF-1 planktonic cells by XTT reduction method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID583470Antimicrobial activity against 5-fluorocytosine resistant Candida glabrata 66032-FC5 harboring Fcy1 A15D mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID574258Antifungal activity against 24 hrs cultures of 10'7 cells/ml Candida albicans SC5314 biofilms by XTT reduction assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID542328Fungicidal activity against Saccharomyces cerevisiae AY-10-R4 mutant after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Discovery of a small-molecule inhibitor of {beta}-1,6-glucan synthesis.
AID565400Antifungal activity against Rhizopus microsporus IHEM 13267 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID568480Antifungal activity against Aspergillus niger KCTC 1231 after 2 days by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and antifungal activity of furo[2,3-f]quinolin-5-ols.
AID405016Antifungal activity against Sporothrix schenckii P25013 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID672345Antifungal activity against Cryptococcus neoformans KCCM 50564 after 1 day2012Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15
Synthesis, antitubercular and antimicrobial evaluation of 3-(4-chlorophenyl)-4-substituted pyrazole derivatives.
AID535403Antifungal activity against flucytosine-resistant Aspergillus fumigatus isolate AZN 58 infected in CD-1 mouse at 100 mg/kg administered every 12 hrs2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus.
AID405221Antimicrobial activity against Blastoschizomyces capitatus IHEM 5666 isolate infected OF1 mouse blastoschizomycosis model assessed as liver microbial count at 60 mg/kg/day, po for 6 days administered 1 hr before microbial challenge2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Combined therapies in a murine model of blastoschizomycosis.
AID563905Antibacterial activity against Candida dubliniensis isolate SA118 of Cd25 fingerprint group 3 and ITS genotype 3 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID1136560Antifungal activity against Trichophyton mentagrophytes ATCC 9129 at <100 ug/ml at pH 7 after 5 days in absence of 10% beef serum1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Antifungal properties of 2-bromo-3-fluorosuccinic acid esters and related compounds.
AID245557Minimum inhibitory concentration was measured against Aspergillus niger KCTC 1231 using modified Sabouraud dextrose broth; (a)2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Synthesis and antifungal activity of noble 5-arylamino- and 6-arylthio-4,7-dioxobenzoselenazoles.
AID284100Antifungal activity against Candida neoformans IM 983040 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID555600Antimicrobial activity against Trichosporon domesticum by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID574249Antifungal activity against 10'7 cells/ml wild-type Candida albicans BF-1 planktonic cells by XTT reduction assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID546070Antifungal activity against Candida parapsilosis isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID546069Antifungal activity against Candida krusei isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID278181Antifungal activity against flucytosine-resistant Cryptococcus neoformans 533 by Etest method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID555592Antimicrobial activity against Trichosporon inkin by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID566890Antifungal activity against Exophiala oligosperma by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID563699Antibacterial activity against 5FC- susceptible Candida dubliniensis isolate SA109T1 harboring plasmid pNIM1 carrying CdFCA1 gene by broth microdilution method in presence of 30 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID565555Antifungal activity against Rhizopus microsporus UTHSC 07-371 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID405068Antifungal activity against Candida krusei ATCC 6258 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID682798Antifungal activity against Aspergillus fumigatus after 72 hrs by broth microdilution method2012European journal of medicinal chemistry, Oct, Volume: 56Micelles catalyzed chemo- and regio-selective one pot and one step synthesis of 2,3,5,6-tetrakis(alkyl and arylsulfanyl)-1,4-benzoquinones and 2,5-diaminosubstituted-1,4-benzoquinones "In-Water" and their biological evaluation as antibacterial and antifun
AID1183072Antifungal activity against Candida tropicalis ATCC MYA-3404/T1 assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID555577Antimicrobial activity against Candida coliculosa by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID245606In vitro minimum inhibitory concentration against Candida tropicalis Berkout KCCM 50662 strain at 37 degree C after 1 day of treatment2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Synthesis and antifungal activity of 5-arylamino-4,7-dioxobenzo[b]thiophenes.
AID425717Antimicrobial activity against Balamuthia mandrillaris ATCC 50209 infected in HBMEC assessed as inhibition of encystment at 10 ug/mL after 7 days2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Effect of antimicrobial compounds on Balamuthia mandrillaris encystment and human brain microvascular endothelial cell cytopathogenicity.
AID1238920Antifungal activity against Candida albicans WTBF-50 by microbroth dilution method2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Synthesis and antifungal evaluation of head-to-head and head-to-tail bisamidine compounds.
AID283352Effect on neutrophils level in intravenously dosed HIV associated cryptococcal meningitis patient relative to control2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID561421Antifungal activity against fcy1(1-26)-deficient Candida lusitaniae by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID519052Antifungal activity against Fusarium sp. after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID306710Antifungal activity against Cryptococcus neoformans KCCM 50564 after 1 day by broth dilution method2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Synthesis and antifungal activity of 6-arylamino-phthalazine-5,8-diones and 6,7-bis(arylthio)-phthalazine-5,8-diones.
AID497819Antifungal activity against Fusarium sp. clinical isolates after 48 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vitro activity of thimerosal against ocular pathogenic fungi.
AID741615Antifungal activity against Candida tropicalis Berkout KCCM 50662 after 1 day by two fold broth dilution method2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Synthesis and antifungal evaluation of 7-arylamino-5,8-dioxo-5,8-dihydroisoquinoline-4-carboxylates.
AID583472Antimicrobial activity against 5-fluorocytosine resistant Candida glabrata 66032-FC1 harboring Fur1 183K mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID583479Antimicrobial activity against 5-fluorocytosine resistant and ura3 harboring Candida glabrata BG14 assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID1136554Antifungal activity against Mucor mucedo ATCC 7941 at <100 ug/ml at pH 7 after 5 days in presence of 10% beef serum1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Antifungal properties of 2-bromo-3-fluorosuccinic acid esters and related compounds.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID323596Antifungal activity against Candida krusei bloodstream isolates by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
AID278154Antifungal activity against flucytosine-resistant Cryptococcus neoformans 285 by checkerboard method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID283377Creatinine clearance in orally dosed HIV associated cryptococcal meningitis patient2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID671985Cytotoxicity in human HepG2 cells assessed as elevation of intracellular calcium concentration by Fluo4AM-fluorescence based high content screening assay2012Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
Synthesis and cytotoxic activity of 4-N-carboxybutyl-5-fluorocytosyl-Arg-Gln-Trp-Arg-Arg-Trp-Trp-Gln-Arg-NH₂.
AID278150Antifungal activity against flucytosine-resistant Cryptococcus neoformans 280 by checkerboard method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID535402Antifungal activity against flucytosine-resistant Aspergillus fumigatus isolate AZN 58 infected in CD-1 mouse at 200 mg/kg administered every 12 hrs2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus.
AID1183064Antifungal activity against Candida glabrata ATCC 90030 assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID278175Antifungal activity against flucytosine-resistant Cryptococcus neoformans 550 by Etest method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID519058Antifungal activity against Candida krusei assessed as susceptible isolates after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID519281Antifungal activity against Candida krusei ATCC 6258 by AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.
AID278144Antifungal activity against flucytosine-resistant Cryptococcus neoformans 285 by checkerboard method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID417268Antifungal activity against Candida isolates by CLSI methods2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing.
AID574261Antifungal activity against 48 hrs cultures of 10'7 cells/ml Candida albicans ATCC 90028 planktonic cells by XTT reduction method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID405107Antimicrobial activity against Mucor sp. after assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID278152Antifungal activity against flucytosine-resistant Cryptococcus neoformans 98.0176 by checkerboard method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID1732075Antifungal activity against Cladosporium-halotolerans SRX7729178 STG-52B assessed as reduction in fungal growth at 0.1 to 3.5 mM measured for 24 days by drop dilution assay relative to control2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel N
AID535688Antibacterial activity against Cryptococcus neoformans serotype AD after 72 hrs by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
AID405056Antifungal activity against Sporothrix schenckii PJRC002 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID563713Antibacterial activity against 5FC- resistant Candida dubliniensis isolate harboring plasmid p7276T3 carrying CdFCA1 gene by broth microdilution method in presence of 25 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID701451Antifungal activity against Candida tropicalis2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
The biology and chemistry of antifungal agents: a review.
AID49468Antifungal activity against Candida albicans ATCC 26278 strain in YNB medium after incorporation of 20 ug per disk.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Synthesis and biological properties of N3-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid dipeptides, a novel group of antimicrobial agents.
AID445513Antifungal activity against Aspergillus flavus KCCM 11899 by twofold broth dilution method2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Synthesis and antifungal activity of benzo[d]oxazole-4,7-diones.
AID574256Antifungal activity against 10'3 cells/ml Candida albicans SC5314 by NCCLS method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID574260Antifungal activity against 24 hrs cultures of 10'7 cells/ml Candida albicans BF-1 planktonic cells by XTT reduction method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID574257Antifungal activity against 10'8 cells/ml Candida albicans SC5314 planktonic cells by XTT reduction assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID568481Antifungal activity against Aspergillus flavus KCCM 11899 after 2 days by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and antifungal activity of furo[2,3-f]quinolin-5-ols.
AID563896Antibacterial activity against 5FC- susceptible Candida dubliniensis isolate SA109T2 harboring plasmid pNIM1 carrying CdFCA1 gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID278149Antifungal activity against flucytosine-resistant Cryptococcus neoformans 276 by checkerboard method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID278145Antifungal activity against flucytosine-resistant Cryptococcus neoformans 550 by checkerboard method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID405048Antifungal activity against Sporothrix schenckii P26187 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID574268Antifungal activity against 24 hrs cultures of 10'7 cells/ml biofilm-derived Candida albicans BF-1 planktonic cells hrs by XTT reduction method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID555578Antimicrobial activity against Candida norvegensis by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID563909Antibacterial activity against Candida dubliniensis isolate SA103 of Cd25 fingerprint group 3 and ITS genotype 3 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID535391Antifungal activity against Aspergillus sp. by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus.
AID1732079Antifungal activity against Microascus-paisii SRX7729192 STG-103 assessed as reduction in fungal growth at 0.1 to 3.5 mM measured for 24 days by drop dilution assay relative to control2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel N
AID537735Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID432802Antifungal activity against Sporothrix mexicana after 72 hrs by microdilution method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
In vitro antifungal susceptibilities of five species of sporothrix.
AID405019Antifungal activity against Sporothrix schenckii P20825 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1136879Antiyeast activity against Candida albicans WD 18-4 assessed as total inhibition of fungal growth after 24 to 48 hrs by microdilution-colorimetric method1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Anticandidal activity of 5-fluorocytosine-peptide conjugates.
AID405111Antimicrobial activity against Absidia corymbifera assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID278383Antifungal activity against Candida lusitaniae 6936 URA3[D95V] derived null mutant fur1delta::URA3 by microdilution assay2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance.
AID678584Antifungal activity against Candida tropicalis Berkout KCCM 50662 after 1 day by twofold broth dilution method2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
Synthesis and antifungal activity of 1-thia-4b-aza-cyclopenta[b]fluorene-4,10-diones.
AID1732073Antifungal activity against Aspergillus SRX7729186 STG-93W assessed as reduction in fungal growth at 0.1 to 3.5 mM measured for 24 days by drop dilution assay relative to control2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel N
AID542333Fungicidal activity against Saccharomyces cerevisiae CT-2a mutant after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Discovery of a small-molecule inhibitor of {beta}-1,6-glucan synthesis.
AID510309Antimicrobial activity against flucytosine, azole, and caspofungin resistant Candida glabrata bloodstream isolate 3 harboring Fur1 G109D mutation serially obtained from hematopoietic stem cell transplant recipient by Etest2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.
AID546078Antifungal activity against Candida kefyr isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID566880Antifungal activity against Candida krusei by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID356368Antifungal activity against Candida albicans ATCC 90028 by sphingolipid reversal assay in presence of 5 ug/mL stearylamine2003Journal of natural products, Aug, Volume: 66, Issue:8
Acetylenic acids inhibiting azole-resistant Candida albicans from Pentagonia gigantifolia.
AID405036Antifungal activity against Sporothrix schenckii P24255 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID741616Antifungal activity against Candida krusei Berkout KCCM 11655 after 1 day by two fold broth dilution method2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Synthesis and antifungal evaluation of 7-arylamino-5,8-dioxo-5,8-dihydroisoquinoline-4-carboxylates.
AID405049Antifungal activity against Sporothrix schenckii P26187 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID563718Antibacterial activity against Candida dubliniensis isolate SA113 by broth microdilution method in presence of 25 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID445512Antifungal activity against Aspergillus niger KCTC 1231 after 2 days by twofold broth dilution method2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Synthesis and antifungal activity of benzo[d]oxazole-4,7-diones.
AID278172Antifungal activity against flucytosine-resistant Cryptococcus neoformans 98.0176 by Etest method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID566877Antifungal activity against Candida albicans by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID278177Antifungal activity against flucytosine-resistant Cryptococcus neoformans 99.1026 by Etest method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID278156Antifungal activity against flucytosine-resistant Cryptococcus neoformans 98.0673 by checkerboard method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID563894Antibacterial activity against Candida dubliniensis isolate SA113 harboring plasmid pNIM1 carrying GFP1T1 gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID563711Antibacterial activity against 5FC- susceptible Candida dubliniensis isolate SA109T2 harboring plasmid pNIM1 carrying CdFCA1 gene by broth microdilution method in presence of 25 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID563926Antibacterial activity against Candida albicans harboring Ser29Leu substitution in the cytosine deaminase gene by EUCAST method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID278176Antifungal activity against flucytosine-resistant Cryptococcus neoformans 98.0673 by Etest method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID563704Antibacterial activity against Candida dubliniensis isolate SA109 by broth microdilution method in presence of 30 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID1366577Antifungal activity against Candida parapsilosis ATCC 22019 after 24 hrs by micro broth dilution method2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Novel potentially antifungal hybrids of 5-flucytosine and fluconazole: Design, synthesis and bioactive evaluation.
AID563927Antibacterial activity against 5FC-resistant Candida dubliniensis by NCCLS M27-A2 broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID519062Antifungal activity against Candida glabrata assessed as resistant isolates after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID561423Antifungal activity against Candida lusitaniae CL38-5 by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID323074Antifungal activity against Cryptococcus neoformans IM 031706 by micro-broth dilution method2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID292704Antifungal activity against Aspergillus niger KCTC 1231 after 2 days by 2-fold broth dilution method2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Synthesis and antifungal activity of 1H-indole-4,7-diones.
AID405045Antifungal activity against Sporothrix schenckii SSA29 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID218494In vitro cytotoxicity against Vero cells.1985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates.
AID563934Antibacterial activity against Candida dubliniensis isolate SA109 harboring plasmid pNIM1 carrying GFP1T2 gene by broth microdilution method in presence of 30 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID278161Antifungal activity against flucytosine-resistant Cryptococcus neoformans 533 by checkerboard method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID1238921Antifungal activity against Candida krusei WTBF-51 by microbroth dilution method2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Synthesis and antifungal evaluation of head-to-head and head-to-tail bisamidine compounds.
AID278381Antifungal activity against Candida lusitaniae 6936 URA3[D95V] derived null mutant fcy2delta::URA3 by microdilution assay2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance.
AID356370Antifungal activity against Candida albicans ATCC 90028 by sphingolipid reversal assay in presence of 30 ug/mL stearylamine2003Journal of natural products, Aug, Volume: 66, Issue:8
Acetylenic acids inhibiting azole-resistant Candida albicans from Pentagonia gigantifolia.
AID672344Antifungal activity against Candida krusei KCCM 11655 after 1 day2012Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15
Synthesis, antitubercular and antimicrobial evaluation of 3-(4-chlorophenyl)-4-substituted pyrazole derivatives.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID283381Creatinine clearance in intravenously dosed HIV associated cryptococcal meningitis patient2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID1536891Antifungal activity against azole-resistant Candida albicans after 24 hrs by resazurin dye based fluorimetric assay2019Bioorganic & medicinal chemistry, 02-15, Volume: 27, Issue:4
Synthesis and antimicrobial activities of N
AID561419Antifungal activity against fcy1-deficient Candida lusitaniae by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID574265Antifungal activity against 48 hrs cultures of 10'7 cells/ml Candida albicans ATCC 90028 biofilms by XTT reduction method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID561420Antifungal activity against REPF URA3 fcy1-deficient Candida lusitaniae by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID561432Antifungal activity against Candida lusitaniae CL42 by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID359610Antifungal activity against Candida albicans 44506 assessed as inhibition of U-14C-adenine incorporation into TCA precipitable material after 1 hr1992Journal of natural products, Nov, Volume: 55, Issue:11
Antifungal activity of meridine, a natural product from the marine sponge Corticium sp.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID561417Antifungal activity against Candida lusitaniae 42720 by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID84060In vitro antiviral activity against Herpes simplex virus -1 strain KOS was evaluated in african green monkey kidney1985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID678587Antifungal activity against Aspergillus niger KCTC 1231 after 2 days by twofold broth dilution method2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
Synthesis and antifungal activity of 1-thia-4b-aza-cyclopenta[b]fluorene-4,10-diones.
AID323072Antifungal activity against Cryptococcus neoformans IM 972751 by microbroth dilution method2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID574259Antifungal activity against 24 hrs cultures of 10'7 cells/ml Candida albicans ATCC 90028 planktonic cells by XTT reduction method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID563705Antibacterial activity against Candida dubliniensis isolate SA113 by broth microdilution method in presence of 30 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID561436Antifungal activity against Candida lusitaniae CL174 by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID323073Antifungal activity against Cryptococcus neoformans IM 031631 by micro-broth dilution method2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID638562Antifungal activity against Candida albicans Berkout KCCM 50235 after 1 day by standard two fold broth dilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and antifungal evaluation of pyrido[1,2-a]indole-1,4-diones and benzo[f]pyrido[1,2-a]indole-6,11-diones.
AID284104Antifungal activity against Candida neoformans IM 00319 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID155106The anti-HIV-1 activity was assayed in activated human peripheral blood mononuclear (PBM) cells, relative to RVT; not determined2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.
AID284108Antifungal activity against Candida neoformans IM 961951 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID535401Antifungal activity against flucytosine-resistant Aspergillus fumigatus isolate AZN 58 infected in CD-1 mouse at 200 mg/kg administered every 6 hrs2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus.
AID678585Antifungal activity against Candida krusei Berkout KCCM 11655 after 1 day by twofold broth dilution method2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
Synthesis and antifungal activity of 1-thia-4b-aza-cyclopenta[b]fluorene-4,10-diones.
AID563910Antibacterial activity against Candida dubliniensis isolate SA107 of Cd25 fingerprint group 3 and ITS genotype 3 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID292702Antifungal activity against Candida krusei Berkout KCCM 11655 after 1 day by 2-fold broth dilution method2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Synthesis and antifungal activity of 1H-indole-4,7-diones.
AID519063Antifungal activity against Candida krusei assessed as resistant isolates after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID546074Antifungal activity against Candida dubliniensis isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID1136545Antifungal activity against Aspergillus niger ATCC 1004 at pH 7 after 5 days in presence of 10% beef serum1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Antifungal properties of 2-bromo-3-fluorosuccinic acid esters and related compounds.
AID445510Antifungal activity against Candida krusei Berkout KCCM 11655 after 1 day by twofold broth dilution method2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Synthesis and antifungal activity of benzo[d]oxazole-4,7-diones.
AID565552Antifungal activity against Rhizopus microsporus UTHSC R-3466 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID561427Antifungal activity against Candida lusitaniae CL26 by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID263331Antifungal activity against Candida albicans KCCM 502352006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
Synthesis and antifungal activity of 6-hydroxycinnolines.
AID84938Antiviral activity against Herpes simplex virus -2 strain MS was evaluated in african green monkey kidney1985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates.
AID563922Antibacterial activity against Candida dubliniensis isolate SA105 of Cd25 fingerprint group 1 and ITS genotype 1 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID510307Antimicrobial activity against flucytosine, azole, and caspofungin resistant Candida glabrata bloodstream isolate 1 serially obtained from hematopoietic stem cell transplant recipient by Etest2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID359611Antifungal activity against Candida albicans 44506 assessed as inhibition of U-14C-leucine incorporation into TCA precipitable material after 1 hr1992Journal of natural products, Nov, Volume: 55, Issue:11
Antifungal activity of meridine, a natural product from the marine sponge Corticium sp.
AID555568Antimicrobial activity against Candida tropicalis by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID45146Antifungal activity against Candida albicans ATCC 102312000Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14
Synthesis and antifungal activities of 5/6-arylamino-4,7-dioxobenzothiazoles.
AID405222Antimicrobial activity against Blastoschizomyces capitatus IHEM 5666 isolate infected OF1 mouse blastoschizomycosis model assessed as spleen microbial count at 60 mg/kg/day, po for 6 days administered 1 hr before microbial challenge2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Combined therapies in a murine model of blastoschizomycosis.
AID283363Fungicidal activity in intravenously dosed HIV associated cryptococcal meningitis patient2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID263333Antifungal activity against Candida krusei KCCM 116552006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
Synthesis and antifungal activity of 6-hydroxycinnolines.
AID563907Antibacterial activity against Candida dubliniensis isolate SA109 of Cd25 fingerprint group 3 and ITS genotype 3 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID278179Antifungal activity against flucytosine-resistant Cryptococcus neoformans 276 by Etest method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID563716Antibacterial activity against Candida dubliniensis harboring plasmid p7276 by broth microdilution method in presence of 25 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID1238922Antifungal activity against Candida glabrata ATCC 90030 WTBF-86 by microbroth dilution method2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Synthesis and antifungal evaluation of head-to-head and head-to-tail bisamidine compounds.
AID565075Antimicrobial activity against Blastoschizomyces capitatus by microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Case of fatal Blastoschizomyces capitatus infection occurring in a patient receiving empiric micafungin therapy.
AID356367Antifungal activity against Candida albicans ATCC 90028 by sphingolipid reversal assay in presence of 5.0 ug/mL dihydrosphingosine2003Journal of natural products, Aug, Volume: 66, Issue:8
Acetylenic acids inhibiting azole-resistant Candida albicans from Pentagonia gigantifolia.
AID563913Antibacterial activity against Candida dubliniensis isolate Eg202 of Cd25 fingerprint group 3 and ITS genotype 4 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID519065Antifungal activity against Candida tropicalis assessed as resistant isolates after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID1136877Antiyeast activity against Saccharomyces cerevisiae 9763 assessed as total inhibition of fungal growth after 24 to 48 hrs by microdilution-colorimetric method1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Anticandidal activity of 5-fluorocytosine-peptide conjugates.
AID563908Antibacterial activity against Candida dubliniensis isolate SA108 of Cd25 fingerprint group 3 and ITS genotype 3 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID278157Antifungal activity against flucytosine-resistant Cryptococcus neoformans 99.1026 by checkerboard method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID520618Antifungal activity against Candida parapsilosis by microdilution AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain.
AID566883Antifungal activity against Aspergillus fumigates by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID535398Half life in CD-1 mouse at 800 mg/kg2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus.
AID1732077Antifungal activity against Ulocladium chartarum SRX7729176 STG-36 assessed as reduction in fungal growth at 0.1 to 3.5 mM measured for 24 days by drop dilution assay relative to control2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel N
AID405195Antimicrobial activity against Blastoschizomyces capitatus IHEM 5666 isolate infected OF1 mouse blastoschizomycosis model assessed as mean survival time at 60 mg/kg/day, po for 6 days administered 1 hr before microbial challenge2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Combined therapies in a murine model of blastoschizomycosis.
AID48635Antifungal activity against Candida tropicalis ATCC 287752000Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14
Synthesis and antifungal activities of 5/6-arylamino-4,7-dioxobenzothiazoles.
AID546079Antifungal activity against Candida lipolytica isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID217969In vitro antiviral activity against Vaccinia virus strain Elstree was evaluated in african green monkey kidney1985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates.
AID555595Antimicrobial activity against Trichosporon jirovecii by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID278382Antifungal activity against Candida lusitaniae 6936 URA3[D95V] derived null mutant fcy1delta::URA3 by microdilution assay2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance.
AID519056Antifungal activity against Candida albicans assessed as susceptible isolates after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID1366578Antifungal activity against Candida albicans after 24 hrs by micro broth dilution method2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Novel potentially antifungal hybrids of 5-flucytosine and fluconazole: Design, synthesis and bioactive evaluation.
AID534347Antifungal activity against Candida albicans grown as planktonic cell after 24 hrs by XTT reduction assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene.
AID284106Antifungal activity against Candida neoformans IM 031631 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID405043Antifungal activity against Sporothrix schenckii P1621 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID306712Antifungal activity against Aspergillus flavus KCCM 11899 after 2 days by broth dilution method2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Synthesis and antifungal activity of 6-arylamino-phthalazine-5,8-diones and 6,7-bis(arylthio)-phthalazine-5,8-diones.
AID574060Antifungal activity against 10'3 cells/ml wild-type Candida albicans BF-1 by NCCLS method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID1238924Antifungal activity against Cryptococcus neoformans Cn18 (Serotype C) WTBF-106 by microbroth dilution method2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Synthesis and antifungal evaluation of head-to-head and head-to-tail bisamidine compounds.
AID563700Antibacterial activity against 5FC- resistant Candida dubliniensis isolate harboring plasmid p7276T3 carrying CdFCA1 gene by broth microdilution method in presence of 30 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID405067Antifungal activity against Candida krusei ATCC 6258 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID563710Antibacterial activity against 5FC- susceptible Candida dubliniensis isolate SA113T1 harboring plasmid pNIM1 carrying CdFCA1 gene by broth microdilution method in presence of 25 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID245594In vitro minimum inhibitory concentration against Candida albicans Berkout KCCM 50235 strain at 37 degree C after 1 day of treatment2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Synthesis and antifungal activity of 5-arylamino-4,7-dioxobenzo[b]thiophenes.
AID565398Antifungal activity against Rhizopus microsporus CBS 102277 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID405011Antifungal activity against Sporothrix schenckii P0019 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID638565Antifungal activity against Cryptococcus neoformans Berkout KCCM 50564 after 1 day by two fold broth dilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and antifungal evaluation of pyrido[1,2-a]indole-1,4-diones and benzo[f]pyrido[1,2-a]indole-6,11-diones.
AID405112Antimicrobial activity against Cunninghamella sp. assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID519060Antifungal activity against Candida tropicalis assessed as susceptible isolates after 48 hrs by broth microdilution2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID1732070Antifungal activity against Aspergillus versicolor SRX7729174 STG-25G assessed as reduction in fungal growth at 0.1 to 3.5 mM measured for 24 days by drop dilution assay relative to control2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel N
AID546075Antifungal activity against Candida guilliermondii isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID672346Antifungal activity against Aspergillus niger KCTC 1231 after 2 days2012Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15
Synthesis, antitubercular and antimicrobial evaluation of 3-(4-chlorophenyl)-4-substituted pyrazole derivatives.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID510308Antimicrobial activity against flucytosine, azole, and caspofungin resistant Candida glabrata bloodstream isolate 2 harboring Fur1 G109D mutation serially obtained from hematopoietic stem cell transplant recipient by Etest2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.
AID555570Antimicrobial activity against Candida krusei by broth microdilution method2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
AID563906Antibacterial activity against Candida dubliniensis isolate SA113 of Cd25 fingerprint group 3 and ITS genotype 4 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID278174Antifungal activity against flucytosine-resistant Cryptococcus neoformans 285 by Etest method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID701471Antifungal activity against Candida krusei2012Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19
The biology and chemistry of antifungal agents: a review.
AID563717Antibacterial activity against Candida dubliniensis isolate SA109 by broth microdilution method in presence of 25 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID1136558Antifungal activity against Trichophyton mentagrophytes ATCC 9129 at <100 ug/ml at pH 5.6 after 5 days in presence of 10% beef serum1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Antifungal properties of 2-bromo-3-fluorosuccinic acid esters and related compounds.
AID1904255Anti-cryptococcal activity against Cryptococcus neoformans H99 assessed as inhibition of fungal growth incubated for 72 hrs by microdilution method2022Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9
Discovery of Novel Sertraline Derivatives as Potent Anti-
AID155571Antiviral activity against Para influenza virus type 3 strain C243 was evaluated in african green monkey kidney1985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates.
AID85090In vitro antiviral activity against Herpes simplex virus -2 strain MS was evaluated in african green monkey kidney1985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates.
AID1136571Antifungal activity against Aspergillus niger ATCC 1004 at pH 5.6 after 5 days in absence of 10% beef serum1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Antifungal properties of 2-bromo-3-fluorosuccinic acid esters and related compounds.
AID278199Antifungal activity against flucytosine-resistant Cryptococcus neoformans 280 at 64 ug/ml after 72 hrs by time-kill method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID356369Antifungal activity against Candida albicans ATCC 90028 by sphingolipid reversal assay in presence of 15 ug/mL stearylamine2003Journal of natural products, Aug, Volume: 66, Issue:8
Acetylenic acids inhibiting azole-resistant Candida albicans from Pentagonia gigantifolia.
AID283354Effect on platelet count in intravenously dosed HIV associated cryptococcal meningitis patient relative to control2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID574269Antifungal activity against 48 hrs cultures of 10'7 cells/ml biofilm-derived Candida albicans ATCC 90028 planktonic cells hrs by XTT reduction method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID283350Effect on hemoglobin level in intravenously dosed HIV associated cryptococcal meningitis patient relative to control2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID574252Antifungal activity against 24 hrs cultures of 10'7 cells/ml Candida albicans ATCC 90028 biofilms by XTT reduction assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID359613Antifungal activity against Candida albicans 44506 assessed as inhibition of U-14C-acetate incorporation into TCA precipitable material after 1 hr1992Journal of natural products, Nov, Volume: 55, Issue:11
Antifungal activity of meridine, a natural product from the marine sponge Corticium sp.
AID405070Antifungal activity against Candida parapsilosis ATCC 22019 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID283374Effect on creatinine clearance in orally dosed HIV associated cryptococcal meningitis patient after 2 weeks relative to baseline2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID405024Antifungal activity against Sporothrix schenckii P14954 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID405062Antifungal activity against Sporothrix schenckii P30915 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID546077Antifungal activity against Candida pelliculosa isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID563924Antibacterial activity against Candida dubliniensis isolate CD36b of Cd25 fingerprint group 1 and ITS genotype 1 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID323069Antifungal activity against Cryptococcus neoformans IM 042074 by micro-broth dilution method2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID278147Antifungal activity against flucytosine-resistant Cryptococcus neoformans 99.1026 by checkerboard method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID741612Antifungal activity against Aspergillus niger KCTC 1231 after 2 days by two fold broth dilution method2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Synthesis and antifungal evaluation of 7-arylamino-5,8-dioxo-5,8-dihydroisoquinoline-4-carboxylates.
AID534351Antifungal activity against Candida albicans TDH3 overexpressing FKS1 gene2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene.
AID638567Antifungal activity against Aspergillus flavus KCCM 11899 after 2 days by two fold broth dilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and antifungal evaluation of pyrido[1,2-a]indole-1,4-diones and benzo[f]pyrido[1,2-a]indole-6,11-diones.
AID48788In vitro antifungal activity against Candida tropicalis ATCC 28775 was measured2003Bioorganic & medicinal chemistry letters, Jan-06, Volume: 13, Issue:1
Synthesis and antifungal activity of 2,5-disubstituted-6-arylamino-4,7-benzimidazolediones.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID566889Antifungal activity against Exophiala spinifera by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID278196Antifungal activity against flucytosine-resistant Cryptococcus neoformans 99.1026 at 64 ug/ml after 72 hrs by time-kill method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID283368Effect on platelet count in orally dosed HIV associated cryptococcal meningitis patient after 2 weeks relative to baseline2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID155120The anti-HIV-1 activity was assayed in activated human peripheral blood mononuclear (PBM) cells, relative to RVT; not determined2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.
AID405009Antifungal activity against Sporothrix schenckii P0019 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID323067Antifungal activity against Cryptococcus neoformans IM 983040 by micro-broth dilution method2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID283356Effect on alanine transferase level in intravenously dosed HIV associated cryptococcal meningitis patient relative to control2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID563912Antibacterial activity against Candida dubliniensis isolate Eg207 of Cd25 fingerprint group 3 and ITS genotype 4 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID565554Antifungal activity against Rhizopus microsporus UTHSC 04-3294 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID563904Antibacterial activity against Candida dubliniensis isolate SA121 of Cd25 fingerprint group 3 and ITS genotype 4 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID678588Antifungal activity against Aspergillus flavus KCCM 11899 after 2 days by twofold broth dilution method2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
Synthesis and antifungal activity of 1-thia-4b-aza-cyclopenta[b]fluorene-4,10-diones.
AID405027Antifungal activity against Sporothrix schenckii MRSS4 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID405025Antifungal activity against Sporothrix schenckii P14954 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID535396Antifungal activity against flucytosine-susceptible Aspergillus fumigatus isolate AZN 58 infected in CD-1 mouse assessed as prolongation of survival at 200 mg/kg administered every 12 hrs2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus.
AID217820Antiviral activity against Vaccinia virus strain Elstree was evaluated in african green monkey kidney1985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID283361Fungicidal activity in HIV associated Cryptococcal meningitis patient2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID554732Inhibition of Candida krusei ABC1 expressed in Saccharomyces cerevisiae isolate ADdelta at 19 nM2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID565403Antifungal activity against Rhizopus microsporus IHEM 4770 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID1183069Antifungal activity against Candida lusitaniae CBS 6936 assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID405047Antifungal activity against Sporothrix schenckii SSA29 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1183067Antifungal activity against Candida kefyr clinical isolate assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID405015Antifungal activity against Sporothrix schenckii P25013 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID405032Antifungal activity against Sporothrix schenckii P24223 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1183071Antifungal activity against Candida parapsilosis ATCC 22019 assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID1732074Antifungal activity against Aspergillus-amoenus SRX7729194 STG-106 assessed as reduction in fungal growth at 0.1 to 3.5 mM measured for 24 days by drop dilution assay relative to control2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel N
AID284101Antifungal activity against Candida neoformans IM 972724 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID1136541Antifungal activity against Aspergillus niger ATCC 1004 at pH 5.6 after 5 days in presence of 10% beef serum1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Antifungal properties of 2-bromo-3-fluorosuccinic acid esters and related compounds.
AID86691In vitro cytotoxicity against HepG2 cells (Hepatocarcinoma from ATCC) by MTT assay2000Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14
Synthesis and antifungal activities of 5/6-arylamino-4,7-dioxobenzothiazoles.
AID302172Antifungal activity against Candida albicans ATCC 90028 after 48 hrs2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Modifications of the chemical structure of terpenes in antiplasmodial and antifungal drug research.
AID278198Antifungal activity against flucytosine-resistant Cryptococcus neoformans 276 at 64 ug/ml after 72 hrs by time-kill method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID405028Antifungal activity against Sporothrix schenckii MRSS4 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID563933Antibacterial activity against Candida dubliniensis isolate SA109 harboring plasmid pNIM1 carrying GFP1T1 gene by broth microdilution method in presence of 30 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID405051Antifungal activity against Sporothrix schenckii PGAC0016 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID283376Oral clearance in HIV associated cryptococcal meningitis patient2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID568476Antifungal activity against Candida albicans KCCM 50235 after 1 day by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and antifungal activity of furo[2,3-f]quinolin-5-ols.
AID405040Antifungal activity against Sporothrix schenckii P10012 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1366576Antifungal activity against Candida albicans ATCC 90023 after 24 hrs by micro broth dilution method2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Novel potentially antifungal hybrids of 5-flucytosine and fluconazole: Design, synthesis and bioactive evaluation.
AID1156866Antimicrobial activity against Trichophyton mentagrophytes after 96 hrs by microbroth dilution method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis of 2,3,6-trideoxy sugar triazole hybrids as potential new broad spectrum antimicrobial agents.
AID678586Antifungal activity against Cryptococcus neoformans KCCM 50564 after 1 day by twofold broth dilution method2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
Synthesis and antifungal activity of 1-thia-4b-aza-cyclopenta[b]fluorene-4,10-diones.
AID519284Antifungal activity against Candida parapsilosis ATCC 22019 by AFST-EUCAST method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.
AID283359Effect on creatinine clearance in orally dosed HIV associated cryptococcal meningitis patient relative to control2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID638563Antifungal activity against Candida tropicalis Berkout KCCM 50662 after 1 day by two fold broth dilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and antifungal evaluation of pyrido[1,2-a]indole-1,4-diones and benzo[f]pyrido[1,2-a]indole-6,11-diones.
AID583467Antimicrobial activity against 5-fluorocytosine resistant Candida glabrata 66032-FC2 harboring Fur1 deltaG73-V81mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID526737Antifungal activity against Aspergillus flavus KCCM 11899 after 2 days2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Synthesis and antifungal activity of benzofuran-5-ols.
AID565551Antifungal activity against Rhizopus microsporus IHEM 15210 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID561424Antifungal activity against Candida lusitaniae CL38-5 expressing URA3 gene by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID405093Antimicrobial activity against Rhizopus arrhizus after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID682797Antifungal activity against Trichophyton mentagrophytes after 96 hrs by broth microdilution method2012European journal of medicinal chemistry, Oct, Volume: 56Micelles catalyzed chemo- and regio-selective one pot and one step synthesis of 2,3,5,6-tetrakis(alkyl and arylsulfanyl)-1,4-benzoquinones and 2,5-diaminosubstituted-1,4-benzoquinones "In-Water" and their biological evaluation as antibacterial and antifun
AID519283Antifungal activity against Candida krusei ATCC 6258 by WIDERYST method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.
AID574251Antifungal activity against 10'8 cells/ml wild-type Candida albicans BF-1 planktonic cells by XTT reduction assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID278380Antifungal activity against Candida lusitaniae 6936 by microdilution assay2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance.
AID405044Antifungal activity against Sporothrix schenckii P1621 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID561418Antifungal activity against Candida lusitaniae 6936 by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID583473Antimicrobial activity against 5-fluorocytosine resistant and ura3 harboring Candida glabrata 66032u-FC6 harboring Fcy1 T92deltastop mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID1136567Antifungal activity against Candida albicans ATCC 10231 at pH 7 after 5 days in absence of 10% beef serum1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Antifungal properties of 2-bromo-3-fluorosuccinic acid esters and related compounds.
AID405022Antifungal activity against Sporothrix schenckii P30019 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID323068Antifungal activity against Cryptococcus neoformans IM 972724 by micro-broth dilution method2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID405053Antifungal activity against Sporothrix schenckii PGAC0016 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID96790In vitro antitumor activity against L1210 cell line in mice; B indicates inactive at 10e-1 mmol/L1985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates.
AID574253Antifungal activity against 24 hrs cultures of 10'7 cells/ml wild-type Candida albicans BF-1 biofilms by XTT reduction assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID638561Antifungal activity against Aspergillus flavus KCCM 11899 after 2 days by twofold broth dilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and antifungal activity of 6,7-bis(arylthio)-quinazoline-5,8-diones and furo[2,3-f]quinazolin-5-ols.
AID1136563Antifungal activity against Candida albicans ATCC 10231 at pH 5.6 after 5 days in absence of 10% beef serum1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Antifungal properties of 2-bromo-3-fluorosuccinic acid esters and related compounds.
AID1136562Antifungal activity against Trichophyton mentagrophytes ATCC 9129 at <100 ug/ml at pH 7 after 5 days in presence of 10% beef serum1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Antifungal properties of 2-bromo-3-fluorosuccinic acid esters and related compounds.
AID563715Antibacterial activity against 5FC- resistant Candida dubliniensis isolate harboring plasmid p7276T1 carrying CdFCA1 gene by broth microdilution method in presence of 25 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID405060Antifungal activity against Sporothrix schenckii P30915 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID283369Effect on platelet count in intravenously dosed HIV associated cryptococcal meningitis patient after 2 weeks relative to baseline2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID583475Antimicrobial activity against 5-fluorocytosine resistant and ura3 harboring Candida glabrata 66032u-FC5 harboring Fcy2L E342stop mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID546080Antifungal activity against Candida pulcherrima isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID434896Antifungal activity against Candida tropicalis isolate 8 in RPMI 1640 medium by broth dilution susceptibility test2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin.
AID1136878Antiyeast activity against Candida albicans clinical isolate 1-V assessed as total inhibition of fungal growth after 24 to 48 hrs by microdilution-colorimetric method1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Anticandidal activity of 5-fluorocytosine-peptide conjugates.
AID29360Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID542327Fungicidal activity against Saccharomyces cerevisiae AY-10 after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Discovery of a small-molecule inhibitor of {beta}-1,6-glucan synthesis.
AID405054Antifungal activity against Sporothrix schenckii PJRC002 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID561431Antifungal activity against Candida lusitaniae CL38 by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID1366579Antifungal activity against Candida tropicalis after 24 hrs by micro broth dilution method2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Novel potentially antifungal hybrids of 5-flucytosine and fluconazole: Design, synthesis and bioactive evaluation.
AID574061Antifungal activity against 10'5 cells/ml Candida albicans ATCC 90028 by EUCAST method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID405103Antimicrobial activity against Rhizopus sp. assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID565556Antifungal activity against Rhizopus microsporus UTHSC 01-983 by broth microdilution method2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.
AID284102Antifungal activity against Candida neoformans IM 042074 after 48 hrs2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and antifungal activity of (Z)-5-arylidenerhodanines.
AID678583Antifungal activity against Candida albicans Berkout KCCM 50235 after 1 day by twofold broth dilution method2012Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
Synthesis and antifungal activity of 1-thia-4b-aza-cyclopenta[b]fluorene-4,10-diones.
AID405037Antifungal activity against Sporothrix schenckii P24255 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID583466Antimicrobial activity against 5-fluorocytosine resistant Candida glabrata 66032-FC4 harboring Fcy1 A15D mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID568477Antifungal activity against Candida tropicalis KCCM 50662 after 1 day by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and antifungal activity of furo[2,3-f]quinolin-5-ols.
AID292703Antifungal activity against Cryptococcus neoformans KCCM 50564 after 1 day by 2-fold broth dilution method2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Synthesis and antifungal activity of 1H-indole-4,7-diones.
AID563923Antibacterial activity against Candida dubliniensis isolate SA101 of Cd25 fingerprint group 1 and ITS genotype 1 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID574250Antifungal activity against 10'8 cells/ml Candida albicans ATCC 90028 planktonic cells by XTT reduction assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID566885Antifungal activity against Aspergillus niger by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID405026Antifungal activity against Sporothrix schenckii P14954 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID405069Antifungal activity against Candida parapsilosis ATCC 22019 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID1775654Antifungal activity against Candida albicans ATCC596302021Journal of natural products, 03-26, Volume: 84, Issue:3
Antiplasmodial Oleanane Triterpenoids from
AID638564Antifungal activity against Candida krusei Berkout KCCM 11655 after 1 day by two fold broth dilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and antifungal evaluation of pyrido[1,2-a]indole-1,4-diones and benzo[f]pyrido[1,2-a]indole-6,11-diones.
AID561425Antifungal activity against Candida lusitaniae CL38-5 expressing FCY2 gene by microdilution method2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.
AID583481Antimicrobial activity against 5-fluorocytosine resistant and ura3 harboring Candida glabrata BG14-FC8 harboring Fcy2L E238-V277dup mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID412146Antifungal activity against Cryptococcus neoformans KCCM 50564 after 1 day2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Synthesis and antifungal activity of 1H-pyrrolo[3,2-g]quinoline-4,9-diones and 4,9-dioxo-4,9-dihydro-1H-benzo[f]indoles.
AID245579Minimum inhibitory concentration was measured against Candida tropicalis ATCC 28775 using modified Sabouraud dextrose broth; (a)2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Synthesis and antifungal activity of noble 5-arylamino- and 6-arylthio-4,7-dioxobenzoselenazoles.
AID1156864Antimicrobial activity against Cryptococcus neoformans after 72 hrs by microbroth dilution method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis of 2,3,6-trideoxy sugar triazole hybrids as potential new broad spectrum antimicrobial agents.
AID682796Antifungal activity against Sporothrix schenckii after 72 hrs by broth microdilution method2012European journal of medicinal chemistry, Oct, Volume: 56Micelles catalyzed chemo- and regio-selective one pot and one step synthesis of 2,3,5,6-tetrakis(alkyl and arylsulfanyl)-1,4-benzoquinones and 2,5-diaminosubstituted-1,4-benzoquinones "In-Water" and their biological evaluation as antibacterial and antifun
AID563714Antibacterial activity against 5FC- resistant Candida dubliniensis isolate harboring plasmid p7276T2 carrying CdFCA1 gene by broth microdilution method in presence of 25 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID1780180Antifungal activity against Cryptococcus neoformans H99S assessed as inhibition of fungal growth measured after 72 hrs by Plate reader assay
AID405061Antifungal activity against Sporothrix schenckii P30915 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID323075Antifungal activity against Cryptococcus neoformans IM 961951 by micro-broth dilution method2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID434892Antifungal activity against Candida tropicalis isolate 4 in RPMI 1640 medium by broth dilution susceptibility test2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin.
AID405098Antimicrobial activity against Mucor circinelloides after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID405042Antifungal activity against Sporothrix schenckii P1621 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID50155In vitro antifungal activity against Candida krusei ATCC 749 was measured2003Bioorganic & medicinal chemistry letters, Jan-06, Volume: 13, Issue:1
Synthesis and antifungal activity of 2,5-disubstituted-6-arylamino-4,7-benzimidazolediones.
AID412143Antifungal activity against Candida tropicalis KCCM 50662 after 1 day2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Synthesis and antifungal activity of 1H-pyrrolo[3,2-g]quinoline-4,9-diones and 4,9-dioxo-4,9-dihydro-1H-benzo[f]indoles.
AID278173Antifungal activity against flucytosine-resistant Cryptococcus neoformans 18476 by Etest method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID283349Effect on hemoglobin level in orally dosed HIV associated cryptococcal meningitis patient relative to control2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID566878Antifungal activity against Candida parapsilosis by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID283362Fungicidal activity in orally dosed HIV associated cryptococcal meningitis patient2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID405035Antifungal activity against Sporothrix schenckii PSCC1 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID283355Effect on alanine transferase level in orally dosed HIV associated cryptococcal meningitis patient relative to control2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID526732Antifungal activity against Candida albicans KCCM 50235 after 1 day2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Synthesis and antifungal activity of benzofuran-5-ols.
AID37716In vitro antifungal activity against Aspergillus niger KCTC 1231 was measured2003Bioorganic & medicinal chemistry letters, Jan-06, Volume: 13, Issue:1
Synthesis and antifungal activity of 2,5-disubstituted-6-arylamino-4,7-benzimidazolediones.
AID741614Antifungal activity against Candida albicans Berkout KCCM 50235 after 1 day by two fold broth dilution method2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Synthesis and antifungal evaluation of 7-arylamino-5,8-dioxo-5,8-dihydroisoquinoline-4-carboxylates.
AID150697In vitro antitumor activity against P388 cell line in mice; B indicates inactive at 10e-1 mmol/L1985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Synthesis and antitumor and antiviral activities of a series of 1-beta-D-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3',5'-monophosphates.
AID574266Antifungal activity against 48 hrs cultures of 10'7 cells/ml Candida albicans BF-1 biofilms by XTT reduction method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID405031Antifungal activity against Sporothrix schenckii P24223 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID245584In vitro minimum inhibitory concentration against Candida krusei Berkout KCCM 11655 strain at 37 degree C after 1 day of treatment2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Synthesis and antifungal activity of 5-arylamino-4,7-dioxobenzo[b]thiophenes.
AID412145Antifungal activity against Candida krusei KCCM 11655 after 1 day2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
Synthesis and antifungal activity of 1H-pyrrolo[3,2-g]quinoline-4,9-diones and 4,9-dioxo-4,9-dihydro-1H-benzo[f]indoles.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID405020Antifungal activity against Sporothrix schenckii P20825 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID563899Antibacterial activity against 5FC- resistant Candida dubliniensis isolate harboring plasmid p7276T2 carrying CdFCA1 gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID1136556Antifungal activity against Trichophyton mentagrophytes ATCC 9129 at <100 ug/ml at pH 5.6 after 5 days in absence of 10% beef serum1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Antifungal properties of 2-bromo-3-fluorosuccinic acid esters and related compounds.
AID49467Antifungal activity against Candida albicans ATCC 26278 strain in YNB medium after incorporation of 10 ug per disk.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Synthesis and biological properties of N3-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid dipeptides, a novel group of antimicrobial agents.
AID283372Effect on aspartate aminotransferase level in orally dosed HIV associated cryptococcal meningitis patient after 2 weeks relative to baseline2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID563925Antibacterial activity against Candida albicans harboring Gly28Asp substitution in the cytosine deaminase gene by EUCAST method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID405052Antifungal activity against Sporothrix schenckii PGAC0016 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by Sensititre YeastOne method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID405101Antimicrobial activity against Cunninghamella sp. after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID563911Antibacterial activity against Candida dubliniensis isolate SA100 of Cd25 fingerprint group 3 and ITS genotype 3 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID563709Antibacterial activity against Candida dubliniensis isolate SA113 harboring plasmid pNIM1 carrying GFP1T1 gene by broth microdilution method in presence of 25 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID1156863Antimicrobial activity against Aspergillus fumigatus after 72 hrs by microbroth dilution method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis of 2,3,6-trideoxy sugar triazole hybrids as potential new broad spectrum antimicrobial agents.
AID638557Antifungal activity against Candida tropicalis Berkout KCCM 50662 after 1 day by twofold broth dilution method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Synthesis and antifungal activity of 6,7-bis(arylthio)-quinazoline-5,8-diones and furo[2,3-f]quinazolin-5-ols.
AID278143Antifungal activity against flucytosine-resistant Cryptococcus neoformans 18476 by checkerboard method2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID566882Antifungal activity against Cryptococcus neoformans by microdilution test2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and antifungal activity of some substituted phenothiazines and related compounds.
AID574267Antifungal activity against 24 hrs cultures of 10'7 cells/ml biofilm-derived Candida albicans ATCC 90028 planktonic cells hrs by XTT reduction method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID542330Fungicidal activity against Saccharomyces cerevisiae AY-10-R15 mutant after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Discovery of a small-molecule inhibitor of {beta}-1,6-glucan synthesis.
AID519286Antifungal activity against Candida parapsilosis ATCC 22019 by WIDERYST method2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.
AID283370Effect on alanine transferase level in orally dosed HIV associated cryptococcal meningitis patient after 2 weeks relative to baseline2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID542336Fungicidal activity against Saccharomyces cerevisiae AY-10 transformed with pRS416-31 carrying KRE6 gene after 24 hrs by microdilution method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Discovery of a small-molecule inhibitor of {beta}-1,6-glucan synthesis.
AID283358Effect on aspartate aminotransferase level in intravenously dosed HIV associated cryptococcal meningitis patient relative to control2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.
AID563916Antibacterial activity against Candida dubliniensis isolate p7718 of Cd25 fingerprint group 3 and ITS genotype 4 by CLSI M27-A2 method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID405030Antifungal activity against Sporothrix schenckii P24223 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID278160Antifungal activity against flucytosine-resistant Cryptococcus neoformans 280 by checkerboard method in presence of amphotericin B2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
AID537734Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1156862Antimicrobial activity against Candida albicans after 48 hrs by microbroth dilution method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis of 2,3,6-trideoxy sugar triazole hybrids as potential new broad spectrum antimicrobial agents.
AID405186Antimicrobial activity against Blastoschizomyces capitatus IHEM 5666 isolate by microdilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Combined therapies in a murine model of blastoschizomycosis.
AID405100Antimicrobial activity against Absidia corymbifera after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID217732Cytotoxicity was determined in Vero cells, relative to RVT2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions.
AID583480Antimicrobial activity against 5-fluorocytosine resistant and ura3 harboring Candida glabrata BG14-FC4 harboring Fcy1 E17stop mutant assessed as lowest concentration inhibiting growth >=80% by broth microdilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Mutational analysis of flucytosine resistance in Candida glabrata.
AID563900Antibacterial activity against 5FC- resistant Candida dubliniensis isolate harboring plasmid p7276T1 carrying CdFCA1 gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID535397Antifungal activity against flucytosine-susceptible Aspergillus fumigatus isolate AZN 58 infected in CD-1 mouse assessed as prolongation of survival at 100 mg/kg administered every 12 hrs2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus.
AID405012Antifungal activity against Sporothrix schenckii PSSA81 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by modified NCCLS M38-A method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID278384Antifungal activity against Candida lusitaniae 6936 revertant fcy2delta::[FCY2-URA3] by microdilution assay2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance.
AID356365Antifungal activity against Candida albicans ATCC 90028 by sphingolipid reversal assay in presence of 1.25 ug/mL dihydrosphingosine2003Journal of natural products, Aug, Volume: 66, Issue:8
Acetylenic acids inhibiting azole-resistant Candida albicans from Pentagonia gigantifolia.
AID563721Antibacterial activity against Candida dubliniensis isolate SA109 harboring plasmid pNIM1 carrying GFP1T1 gene by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID323071Antifungal activity against Cryptococcus neoformans IM 00319 by microbroth dilution method2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.
AID1183061Antifungal activity against Candida albicans SC5314 ATCC MYA-2876 assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID405113Antimicrobial activity against Apophysomyces elegans assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID405038Antifungal activity against Sporothrix schenckii P24255 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID405071Antifungal activity against Candida parapsilosis ATCC 22019 isolate from cutaneous-lymphatic sporotrichosis patient after 72 hrs by ATB Fungus 2 method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
AID546081Antifungal activity against Candida intermedia isolated from candidemia patient by AFST-EUCAST microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece.
AID526734Antifungal activity against Candida krusei KCCM 11655 after 1 day2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Synthesis and antifungal activity of benzofuran-5-ols.
AID563930Antibacterial activity against 5FC- susceptible Candida dubliniensis isolate SA109T2 harboring plasmid pNIM1 carrying CdFCA1 gene by broth microdilution method in presence of 30 ug/ml DOX2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID245558Minimum inhibitory concentration was measured against Candida albicans ATCC 10231 using modified Sabouraud dextrose broth; (a)2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Synthesis and antifungal activity of noble 5-arylamino- and 6-arylthio-4,7-dioxobenzoselenazoles.
AID574264Antifungal activity against 24 hrs cultures of 10'7 cells/ml Candida albicans BF-1 biofilms by XTT reduction method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1732078Antifungal activity against Simplicilium-lamellicola SRX772919 STG-96 assessed as reduction in fungal growth at 0.1 to 3.5 mM measured for 24 days by drop dilution assay relative to control2021European journal of medicinal chemistry, Apr-05, Volume: 215Discovery of novel N
AID405109Antimicrobial activity against Rhizomucor sp. assessed as percent of susceptible isolates after 24 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
AID568478Antifungal activity against Candida krusei KCCM 11655 after 1 day by twofold broth dilution method2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Synthesis and antifungal activity of furo[2,3-f]quinolin-5-ols.
AID563903Antibacterial activity against Candida dubliniensis isolate SA113 by broth microdilution method2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,577)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990958 (37.18)18.7374
1990's525 (20.37)18.2507
2000's570 (22.12)29.6817
2010's418 (16.22)24.3611
2020's106 (4.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.04 (24.57)
Research Supply Index7.96 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index114.24 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (64.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials85 (3.07%)5.53%
Reviews291 (10.49%)6.00%
Case Studies672 (24.23%)4.05%
Observational5 (0.18%)0.25%
Other1,720 (62.03%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (31)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I/II Safety, Pharmacokinetic, and Pharmacodynamic Study of APS001F With Flucytosine and Maltose for the Treatment of Advanced and/or Metastatic Solid Tumors [NCT01562626]Phase 1/Phase 275 participants (Anticipated)Interventional2012-09-30Suspended
A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma [NCT01156584]Phase 154 participants (Actual)Interventional2010-07-31Completed
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas [NCT01172964]Phase 115 participants (Actual)Interventional2010-08-31Completed
A Phase 1b Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma [NCT02576665]Phase 121 participants (Actual)Interventional2016-07-31Terminated(stopped due to Sponsor decision)
A Phase I, Open-label, Dose-escalating Study of the Safety or Percutaneous Intra-tumoral Injection of TG4023 (MVA-FCU1) Combined With Systemic Administration of 5-fluorocytosine in Patients With Primary or Secondary Hepatic Tumors. [NCT00978107]Phase 116 participants (Actual)Interventional2009-09-30Completed
A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temoz [NCT04105374]Phase 2/Phase 30 participants (Actual)Interventional2020-01-31Withdrawn(stopped due to NCI approval withdrawn)
Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis in Patients With HIV Infection [NCT04532463]30 participants (Actual)Observational2020-10-01Completed
A Multi-center, Prospective, Randomized Trial of Amphotericin B in the Initial Antifungal Therapy for Non-HIV Cryptococcal Meningitis Patients [NCT06178627]Phase 4250 participants (Anticipated)Interventional2023-08-13Enrolling by invitation
Toca 8: A Multicenter, Open-Label, Phase 1 Study to Evaluate the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer [NCT04089163]Phase 10 participants (Actual)Interventional2019-12-31Withdrawn(stopped due to Sponsor decision.)
Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis [NCT00000708]120 participants InterventionalCompleted
A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extende [NCT01985256]Phase 117 participants (Actual)Interventional2014-02-28Completed
A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis [NCT00000639]400 participants InterventionalCompleted
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 [NCT04327011]Phase 165 participants (Actual)Interventional2011-02-28Terminated(stopped due to Sponsor decision)
The Toca 7 Study: A Phase 1b Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care [NCT02598011]Phase 10 participants (Actual)Interventional2017-01-31Withdrawn(stopped due to Sponsor decision)
A Multicenter, Randomized Study to Assess the Efficacy and Safety of Mycograb® as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS [NCT00847678]Phase 238 participants (Actual)Interventional2006-08-31Terminated
Antifungal Treatment of Cryptococcal Meningitis [NCT04140461]Phase 340 participants (Anticipated)Interventional2020-01-02Not yet recruiting
A Phase 1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC [NCT01470794]Phase 158 participants (Actual)Interventional2012-02-29Completed
Clinical Study of Amphotericin B Colloidal Dispersion (ABCD) in the Treatment of Cryptococcal Meningitis [NCT05471063]30 participants (Anticipated)Interventional2022-08-22Not yet recruiting
A Phase I Open-label, Safety Study of Intra-tumoral Application of TMV-018 in Combination With 5-FC or Anti-PD-1 Therapy in Patients With Tumors of the Gastrointestinal Tract [NCT04195373]Phase 10 participants (Actual)Interventional2020-11-23Withdrawn(stopped due to Study not started, no subjects recruited.)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase II Study of the Safety and Antifungal Activity of Subcutaneous Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) in Conjunction With Standard Therapy in Patients With Acute Cryptococcal Men [NCT00012467]Phase 260 participants Interventional2000-01-31Completed
Prospective Pilot Study to Evaluate a Standardized Management of Cryptococcal Meningitis in Patients Infected With HIV in Sub-Saharan Africa Involving an Initial Combination Therapy With Fluconazole and Flucytosine in High Doses, Complemented by Repeat Lu [NCT01715922]Phase 2/Phase 341 participants (Actual)Interventional2012-05-31Active, not recruiting
An Open Label Randomized Controlled Phase IIb Trial to Determine the Safety of Oral Fluconazole in Combination With Flucytosine as Compared to Fluconazole Alone [NCT01562132]Phase 26 participants (Actual)Interventional2013-09-30Terminated(stopped due to Stopped in accordance with pre-specified stopping rules for poor recruitment.)
Dexamethasone in Cryptococcal Meningitis [NCT00000776]Phase 236 participants InterventionalCompleted
Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis [NCT00002305]0 participants InterventionalCompleted
A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis. [NCT00002113]64 participants InterventionalCompleted
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma [NCT02414165]Phase 2/Phase 3403 participants (Actual)Interventional2015-11-30Terminated(stopped due to Sponsor Decision)
Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis [NCT00002075]0 participants InterventionalCompleted
A Dose-escalation and Phase IIa Study of TG6002 Plus Flucytosine in Patients With Unresectable Colorectal Cancer With Liver Metastases [NCT04194034]Phase 1/Phase 215 participants (Actual)Interventional2020-01-17Terminated(stopped due to Study has been terminated after Phase I part on 23 February 2023)
A Phase I/IIa Study of TG6002 (VV TK-RR-FCU1) Administered by Intravenous (IV) Infusions in Combination With Oral Flucytosine (5-FC) in Patients With Advanced Gastro-intestinal (GI) Tumors. [NCT03724071]Phase 1/Phase 251 participants (Actual)Interventional2018-10-16Terminated(stopped due to Study has been terminated after Phase I part on 23 February 2023)
A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination With Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas [NCT02015819]Phase 116 participants (Actual)Interventional2014-10-07Completed
Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients [NCT03294486]Phase 1/Phase 278 participants (Anticipated)Interventional2017-10-12Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01562132 (1) [back to overview]Number of Participants Alive at 12 Weeks
NCT02015819 (6) [back to overview]Average Steady State Levels of 5-FC Concentrations in Plasma
NCT02015819 (6) [back to overview]Comparison of 5-FC in the Brain to 5-FC in the Plasma
NCT02015819 (6) [back to overview]Number of Participants Developing Antibodies Against NSCs
NCT02015819 (6) [back to overview]Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD)
NCT02015819 (6) [back to overview]Number of Participants With Mechanical Issues With Repeat Administrations of NSCs Via Rickham
NCT02015819 (6) [back to overview]Average Steady State Levels of 5-FC and 5-FU in the Brain

Number of Participants Alive at 12 Weeks

(NCT01562132)
Timeframe: 12 weeks

Interventionparticipants (Number)
5FC Plus Fluconazole2
Fluconazole Alone2

[back to top]

Average Steady State Levels of 5-FC Concentrations in Plasma

PK data from the patients who undergo intracerebral microdialysis (dose level 4) will be summarized using descriptive statistics. (NCT02015819)
Timeframe: Samples were obtained prior to the first dose of 5-FC then every 30 minutes for 3 hours, additional samples at 4 and 6 hours after the morning doses on days 4, 5. On days 6, 7, 8 blood samples were collected just before morning dose and 90 minutes later

Interventionµmol/L (Mean)
Dose Level 4 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg) + Leucovorin + Microdialysis748

[back to top]

Comparison of 5-FC in the Brain to 5-FC in the Plasma

PK data from the patients who undergo intracerebral microdialysis (dose level 4) will be summarized using the mean ratio of average brain interstitial 5-FC concentrations to the average steady-state plasma levels. (NCT02015819)
Timeframe: The ratio of average brain interstitial 5-FC and 5-FU concentrations to average plasma steady-state levels was calculated using all measured data.

Interventionratio (Mean)
Dose Level 4 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg) + Leucovorin + Microdialysis29

[back to top]

Number of Participants Developing Antibodies Against NSCs

Development of a antibody response to the NSCs will be evaluated by flow cytometry. Data from assessing for possible development of NSC immunogenicity with repeat exposure will be presented in an exploratory fashion using descriptive statistics. (NCT02015819)
Timeframe: While receiving treatment, up to 6 months.

InterventionParticipants (Count of Participants)
Dose Level 1 (NSC 5x10^7 and 5-FC 37.5 mg/kg)0
Dose Level 2 (NSC 1x10^8 and 5-FC 37.5 mg/kg)2
Dose Level 3 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg)0
Dose Level 4 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg) + Leucovorin + Microdialysis1

[back to top]

Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD)

Number of DLTs per dose level and the MTD/MFD. (NCT02015819)
Timeframe: Day 28 of course 1

InterventionParticipants (Count of Participants)
Dose Level 1: (NSC 5x10^7 and 5-FC 37.5 mg/kg)0
Dose Level 2: (NSC 1x10^8 and 5-FC 37.5 mg/kg)0
Dose Level 3 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg)0
Dose Level 4 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg + Leucovorin + Microdialysis1

[back to top]

Number of Participants With Mechanical Issues With Repeat Administrations of NSCs Via Rickham

Number of participants with mechanical issues with repeat administrations of NSCs via Rickham. (NCT02015819)
Timeframe: 28 days after last infusion of NSCs, up to 6 months total

InterventionParticipants (Count of Participants)
Dose Level 1 (NSC 5x10^7 and 5-FC 37.5 mg/kg)0
Dose Level 2 (NSC 1x10^8 and 5-FC 37.5 mg/kg)0
Dose Level 3 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg)0
Dose Level 4 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg) + Leucovorin + Microdialysis0

[back to top]

Average Steady State Levels of 5-FC and 5-FU in the Brain

Pharmacokinetic (PK) data from the patients who undergo intracerebral microdialysis (dose level 4) will be summarized using descriptive statistics. All summaries will be exploratory in spirit. (NCT02015819)
Timeframe: Following the first dose of 5-FC, samples were collected every hour for 24 hours and then every 3 hours thereafter until the end of the 7-day course of 5-FC or until the microdialysis catheter stopped functioning.

Interventionµmol/L (Mean)
average steady state levels of 5-FC in the brainaverage steady state levels of 5-FU in the brain
Dose Level 4 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg) + Leucovorin + Microdialysis2130.03

[back to top]